US Pat. No. 10,189,770

PRODUCTION METHOD OF HIGHLY UNSATURATED FATTY ACID ETHYL ESTER

Bizen Chemical Co., Ltd.,...

1. A method of purifying highly unsaturated fatty acid derivatives from a mixture comprising highly unsaturated fatty acid derivatives, comprising a step selected from the group consisting of the following (1) to (4):(1) (a) providing the mixture having a peroxide value (POV) of 1 or smaller, wherein the peroxide value of the mixture is adjusted by a POV reducing agent, and
(b) contacting the mixture with an aqueous solution of silver salt;
(2) (a) providing the mixture having a peroxide value of 1 or smaller, wherein the peroxide value of the mixture is adjusted by a POV reducing agent, and
(b) mixing the mixture with an aqueous solution of silver salt;
(3) (a) decreasing a peroxide value of the mixture to 1 or smaller by contacting the mixture with a POV reducing agent, and
(b) contacting the mixture with an aqueous solution of silver salt; and
(4) (a) decreasing a peroxide value of the mixture to 1 or smaller by contacting the mixture with a POV reducing agent, and
(b) mixing the mixture with an aqueous solution of silver salt,
wherein the derivatives comprise at least one of a methyl ester, ethyl ester, amide, methyl amide, triglyceride, diglyceride or monoglyceride derivative.
US Pat. No. 10,190,027

HOT MELT ADHESIVE

1. A hot melt adhesive comprising:(A) 1-15 wt % of a polar functional group-modified conjugated diene-based polymer;
(B) 10-50 wt % of a butyral resin;
(C) 5-40 wt % of an olefin-based polymer;
(D) 5-70 wt % of a tackifier resin; and
(E) 10-40 wt % of a wax.
US Pat. No. 10,191,051

COMPOSITIONS AND METHODS FOR IMPROVED CELL-BASED BOTULINUM NEUROTOXIN ASSAYS

BIOMADISON, INC., Del Ma...

1. A method of increasing the sensitivity of cell-based detection of a botulinum toxin, comprising:(i) providing, in a first media having a sodium concentration greater than 65 mM, a transfected cell that produces a construct comprising;
(a) a terminus comprising a reporter-containing portion, wherein the reporter-containing portion exhibits a signal; and,
(b) a cleavage site that interacts with the botulinum toxin in a manner that produces a cleavage of the reporter-containing portion from a remainder of the construct;
(ii) transferring the transfected cell to a second media having a sodium concentration of less than 50 mM;
(iii) contacting the transfected cell with the botulinum toxin; and
(iv) obtaining the signal from the reporter-containing portion.
US Pat. No. 10,188,747

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

The General Hospital Corp...

1. A method of treating squamous cell carcinoma in a subject in need of treatment thereof, the method comprising administering to the subject an agonist of a gene selected from the group consisting of:Esr2; Dlx5; and Egr3.
US Pat. No. 10,189,772

MIXTURES OF CHELATING AGENTS INCLUDING AN L-ENANTIOMER-RICH MGDA, AND PROCESS FOR MAKING SUCH MIXTURES

BASF SE, Ludwigshafen (D...

1. A mixture, comprising:(A) 90 to 99.9% by weight of a mixture of L- and D-enantiomers of methyl glycine diacetic acid (MGDA) or its respective mono-, di- or trialkali metal or mono-, di- or triammonium salts, said mixture containing predominantly the respective L-enantiomer with an enantiomeric excess (ee) in the range of from 10 to 99%, and
(B) in total 0.1 to 10% by weight of a diacetic acid derivative of at least one amino acid selected from the group consisting of valine, leucine, isoleucine, and tyrosine, as free acids or respective mono-, di- or trialkali metal or mono-, di- or triammonium salts,
wherein the percentages refer to the sum from (A) and (B).
US Pat. No. 10,190,029

REMOVABLE POLYURETHANE HOT MELT ADHESIVE AND THE USE THEREOF

1. A removable reactive hot melt adhesive comprising a (meth)acrylate polymer and an isocyanate-functional polyurethane prepolymer, wherein the (meth)acrylate polymer has a number average molecular weight from about 25000 g/mol to about 60000 g/mol and is selected from a copolymerization product of butyl acrylate and methyl methacrylate as monomers having a melting point of from about 100° C. to about 120° C., a copolymerization product of butyl methacrylate and methyl methacrylate as monomers having a melting point about 110° C., and combinations thereof; andwherein the cured adhesive has a bond strength of about 5.0 MPa or greater at room temperature and a bond strength of about 0.8 MPa or less at a temperature of about 70° C. to about 90° C.
US Pat. No. 10,188,748

PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED MRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS

1. A cell-free mRNA pharmaceutical composition comprising at least one modified mRNA and a pharmaceutically compatible carrier, wherein the modified mRNA encodes at least one human tumour-specific antigenic polypeptide capable of stimulating an immune response in a patient against the human tumour-specific antigenic polypeptide wherein said modified mRNA encoding the human tumour-specific antigenic polypeptide has been stabilized by increasing its Guanosine/Cytosine (G/C) content by at least 7 percentage points relative to that of the wild type mRNA encoding the tumour-specific antigenic polypeptide.
US Pat. No. 10,188,749

COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS

FRED HUTCHINSON CANCER RE...

1. A method of selectively modifying a selected cell population of hematopoietic origin comprising:(a) forming selected cell-targeted synthetic nanocarriers by
(i) adding polyglutamic acid (PGA) conjugated to selected cell targeting ligands that bind the selected cell population of hematopoietic origin to a solution comprising nucleic acid encapsulated within a positively-charged carrier comprising poly(?-amino ester); and
(ii) incubating the solution wherein selected cell-targeted synthetic nanocarriers form within 5 minutes of the adding and comprise
(A) nucleic acid encapsulated within the positively-charged carrier comprising poly(?-amino ester);
(B) a neutrally or negatively-charged coating comprising about a 15 kDa PGA on the outer surface of the positively-charged carrier; and
(C) the selected cell targeting ligands extending from the outer surface of the neutrally or negatively-charged coating and conjugated to PGA within the neutrally or negatively-charged coating; and
(b) administering the formed selected cell-targeted synthetic nanocarriers to a heterogenous mixture of ex vivo cells comprising the selected cell population of hematopoietic origin within a serum-free media thereby selectively modifying the selected cell population of hematopoietic origin.
US Pat. No. 10,190,031

THERMALLY CONDUCTIVE INTERFACE COMPOSITION AND USE THEREOF

Jiali Wu, Yorktown Heigh...

1. A thermally conductive interface composition, comprising:(A) A linear alkenyl organopolysiloxane containing a silicon-bonded alkenyl-terminated group or groups in an average amount of 0.0001 to 5 mol % based on the amount of all silicon-bonded organic groups contained per molecule;
(B) A branched alkenyl organopolysiloxane containing at least two silicon-bonded alkenyl groups in an average amount of about 0.01 to 1 mol % based on the amount of all silicon-bonded organic groups contained per molecule, with component (A) to (B) ratio of 20:1 to 1:20;
(C) Thermally conductive fillers in a ternary particle size mixture with large particle in the average size range of 50-500 um, small particle in the average size range of 0.5-200 um, and nanoparticle in the average size range of 10-2000 nm;
(D) An organohydrogenpolysiloxane containing at least two Si—H terminated groups presented at terminal or intermediate positions of the molecule, with 0.5-0.8 moles of SiH groups per mole of alkenyl groups in component (A) and (B);
(E) An addition reaction catalyst;
(F) A hydroxy group-containing siloxane in an amount corresponding to 0.0001-5% of the weight of component (A) and (B) combined;
(G) A mixture of at least two alkoxy group-containing siloxanes adhering to formula (5) differing in the value of “n” added in an amount corresponding to 0.001-5% of the weight of component (C)
(R8O)pSiR93-p[OSiR82]n(OR8)qR93-q  (5)
wherein R8 and R9 represent a substituted or unsubstituted monovalent hydrocarbon group, p is an integer of 1, 2, 03, q is an integer of 1, 2, or 3, and n is an integer of 1 to 150.
US Pat. No. 10,191,055

DETECTION OF ACUTE MYELOID LEUKAEMIA (AML) LEUKAEMIC STEM CELLS (LSC)

OXFORD UNIVERSITY INNOVAT...

2. The method according to claim 1 further comprising contacting the isolated sample with one or more selected from the group consisting of:an antibody that specifically binds to CD2;
an antibody that specifically binds to CD3;
an antibody that specifically binds to CD4;
an antibody that specifically binds to CD8a;
an antibody that specifically binds to CD10;
an antibody that specifically binds to CD19;
an antibody that specifically binds to CD20; and
an antibody that specifically binds to CD235a.
US Pat. No. 10,188,750

SELF-REPLICATING CELL SELECTIVE GENE DELIVERY COMPOSITIONS, METHODS, AND USES THEREOF

University of South Flori...

1. A polyribonucleotide comprising:a RNA molecule of interest (ROI), wherein the ROI is an RNA capable of being translated into p27;
a microRNA (miRNA) target sequence, wherein the miRNA target sequence is a target for miR-126, and wherein the miRNA target sequence is operatively linked to the ROI; and
a RNA molecule capable of being translated into a viral RNA replicase, wherein the RNA molecule capable of being translated into a viral RNA replicase is operatively linked to the ROI, the miRNA target sequence, or both the ROI and miRNA target sequence.
US Pat. No. 10,191,056

DIAGNOSTIC EVALUATION OF ANTIBODY RESPONSES TO COMMONLY RECOGNIZED PROSTATE CANCER-ASSOCIATED ANTIGENS

Wisconsin Alumni Research...

1. An antigen panel for identifying immunoreactivity associated with a premalignant or malignant prostate, the panel comprising antigens encoded by SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:64, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:91, the encoded antigens being immobilized on one of a membrane, a plate, and a filter, and having a positive likelihood ratio of at least 4.
US Pat. No. 10,188,751

PAPILLOMAVIRUS PSEUDOVIRUSES FOR DETECTION AND THERAPY OF TUMORS

The United States of Amer...

1. A method comprising administering to cancer cells in a subject, a papilloma pseudovirus that comprises a fluorescent dye or a papilloma virus-like particle (VLP) that comprises a fluorescent dye, and exposing the fluorescent dye in the cancer cells in the subject to an excitation wavelength of light.
US Pat. No. 10,189,008

ODOR AND COLOR STABLE WATER-ABSORBING COMPOSITION

Evonik Degussa GmbH, Ess...

1. A water-absorbing composition comprising at least: i) from 91.2 to 98.9 wt % of at least one water-absorbing polymer; ii) from 1 to 8 wt % of at least one oxidizing agent; and iii) from 0.1 to 0.75 wt % of at least one inhibitor to inhibit free-radical polymerizations; wherein the inhibitor is a hydroquinone or a hydroquinone derivative selected from the group consisting of hydroquinone, hydroquinone monomethyl ether (HQME), 1,4-dimethoxybenzene, 4,4?-oxydiphenol and a mixture of two or more thereof; and wherein the weight quantities are each based on the overall weight of the water-absorbing composition.
US Pat. No. 10,191,057

METHODS OF DIAGNOSING, CLASSIFYING AND TREATING ENDOMETRIAL CANCER AND PRECANCER

The Translational Genomic...

1. A method of treating endometrial cancer characterized by FGFR2 activation in a subject, the method comprising:obtaining from the subject a biological sample comprising endometrial cancer cells;
screening for a FGFR2 activation mutation in the endometrial cancer cells wherein the FGFR2 activation mutation results in an amino acid substitution selected from the group consisting of:
(a) an S to W mutation at position 252 of SEQ ID NOS:2 (NP_075259.2) or 3 (NP_000132.1);
(b) a P to R mutation at position 253 of SEC) ID NOS:2 or 3;
(c) a K to R mutation at position 310 of SEC) ID NOS:2 or 3;
(d) an A to T mutation at position 315 of SEQ ID NOS:2 or 3;
(e) an S to C mutation at position 373 of SEQ ID NO:2 or position 372 of SEQ ID NO:3;
(f) a Y to C mutation at position 376 of SEQ ID NO:2 or position 375 of SEQ ID NO:3;
(g) a C to R mutation at position 383 of SEQ ID NO:2 or position 382 of SEQ ID NO:3;
(h) an M to R mutation at position 392 of SEQ ID NO:2 or position 391 of SEQ ID NO:3;
(i) an I to V mutation at position 548 of SEQ ID NO:2 or position 547 of SEQ ID NO:3;
(j) an N to K mutation at position 550 of SEQ ID NO:2 or position 549 of SEQ ID NO:3;
(k) a K to E mutation at position 660 of SEQ ID NO:2 or position 659 of SEQ ID NO:3; and
(l) a K to N mutation at position 660 of SEQ ID NO:2 or position 659 of SEQ ID NO:3;
identifying the endometrial cancer cells as susceptible to an FGFR2 inhibitor upon finding the FGFR2 activation mutation in the endometrial cancer cells; and
administering to the subject with endometrial cancer characterized by FGFR2 activation an effective amount of an FGFR2 inhibitor, wherein the FGFR2 inhibitor is PD173074.
US Pat. No. 10,188,752

DUAL-MODALITY IMAGING PROBE FOR COMBINED LOCALIZATION AND APOPTOSIS DETECTION OF STEM CELLS

The Board of Trustees of ...

1. A dual-modality imaging probe for simultaneous, one-stop, cell apoptosis detection and stem cell tracking, comprising: ferumoxytol with a fluorescent signature peptide immobilized on the surface of the ferumoxytol, wherein the fluorescent signature peptide is a KKKKDEVD-AFC peptide (SEQ ID NO:1).
US Pat. No. 10,189,009

PARTICULATE WATER ABSORBING AGENT AND METHOD FOR MANUFACTURING SAME

NIPPON SHOKUBAI CO., LTD....

1. A method for producing a particulate water absorbing agent, the particulate water absorbing agent being arranged such that particles having passed through a 150-?m mesh as defined through a standard-sieve classification are contained in an amount of 3 mass % or less, the method comprising the steps of:(1) polymerizing a monomer aqueous solution including acrylic acid (salt) as a main component, the monomer aqueous solution having a monomer concentration of 30 mass % or more, the polymerization involving use of an internal crosslinking agent in an amount of 0.04 mol % or more and 0.07 mol % or less relative to the monomer and producing a hydrogel;
(2) drying the hydrogel, produced through the step (1), to produce a dried product having a swelling rate (CRC) of 35 g/g to 55 g/g;
(3) pulverizing the dried product into particles and optionally classifying the particles to produce a water absorbent resin powder including, at 80 mass % or more relative to the entire water absorbent resin powder, a particle having a size of 600 ?m to 150 ?m as defined through a standard-sieve classification;
(4) adding a surface-crosslinking agent, which includes a compound containing a hydroxyl group and/or a derivative group thereof, to the water absorbent resin powder, produced through the step (3), to decrease the swelling rate (CRC) by 3 g/g to 15 g/g to a swelling rate (CRC) of 32 g/g to 50 g/g to produce a surface-crosslinked water absorbent resin powder, and
(5) adding a liquid permeability improving agent to the water absorbent resin powder simultaneously with and/or after the step (4).
US Pat. No. 10,191,058

DIAGNOSIS OF CANCER BY DETECTING AUTO-ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR)

CELLTREND GMBH, Luckenwa...

1. A method for treating a vascular endothelial growth factor receptor (VEGFR) or vascular endothelial growth factor (VEGF) associated cancer, comprising(i) determining the level of antibodies against VEGFR in a sample from a subject suspected of having such cancer,
(ii) comparing the determined level in the sample to a control level of VEGFR antibodies derived from subjects without cancer;
(iii) identifying a subject having a decreased level of said antibodies in the subject's sample as compared to the level of said antibodies in the control, and
(iv) administering to the subject from step (iii) a drug selected from the group consisting of an angiogenesis inhibitor, an anti-VEGF antibody, and bevacizumab.
US Pat. No. 10,189,778

PROCESS FOR THE PREPARATION OF METHIONINE ALPHA-HYDROXY ANALOGUES FROM SUGARS AND DERIVATIVES THEREOF

1. A process for the preparation of a methionine ?-hydroxy analogue and derivatives thereof of the formula:R?—S—CH2—CH2—CHOH—COO—R  (I)wherein R is selected from the group consisting of H, C1-C8 alkyl, alkaline or alkaline-earth metals; and R? is selected from the group consisting of H and methyl; andwherein the process comprises a step of contacting one or more sugars or derivatives thereof selected from the group consisting of glucose, fructose, galactose, mannose, sucrose, xylose, erythrose, erythrulose, threose, glycolaldehyde, methyl vinyl glycolate,vinyl glycolic acid and 2-hydroxyl-?-butyrolactone with a metallo-silicate zeotype material, in the presence of a compound comprising sulphur and a solvent, wherein the metallo-silicate zeotype material has a framework structure selected from the group consisting of BEA, MFI, FAU, MOR, and FER, with a metal and/or metal oxide component.
US Pat. No. 10,191,059

IN VITRO METHOD FOR THE PROGNOSIS OF PROGRESSION OF A CANCER AND OF THE OUTCOME IN A PATIENT AND MEANS FOR PERFORMING SAID METHOD

Institut National de la S...

1. A method for treating a patient suffering from a solid cancer comprising the steps of:(i) evaluating the intra-tumor adaptive immune status of said patient before administration of an anti-cancer agent by quantifying, in a pre-administration tumor sample, at least two biological markers indicative of the status of the adaptive immune response of said patient against cancer, wherein two of said at least two biological markers are PDCD1LG1 combined with CD8A,
(ii) administering an anti-cancer agent to the patient,
(iii) evaluating the intra-tumor adaptive immune status of said patient after administration of said anti-cancer agent by quantifying in a post-administration tumor sample said at least two biological markers indicative of the status of the adaptive immune response of said patient against cancer,
(iv) comparing the levels of said at least two biological markers quantified in steps (i) with the levels of said at least two biological markers quantified in step (iii),
(v) administering to the patient:
a PDCD1LG1 inhibitor and/or a PDCD1 inhibitor to the patient when the level of PDCD1LG1 has increased between steps (i) and (iii); and/or
an immuno-stimulatory agent when the level of CD8A has not increased between step (i) and step (iii).
US Pat. No. 10,189,779

METHODS FOR PRODUCING THIOL COMPOUNDS AND SULFIDE COMPOUNDS USING DIPHENYLAMINE OR A PHENOL COMPOUND

Chevron Phillips Chemical...

1. A process for producing a thiol compound, the process comprising:i) contacting:
a) an olefin compound;
b) H2S;
c) diphenylamine and/or a phenol compound comprising BHT, carvacrol, 2,2?-ethylidene-bis(4,6-di-tert-butylphenol), pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate), or any combination thereof; and
d) a photoinitiator and/or a free radical initiator; and
ii) forming the thiol compound.
US Pat. No. 10,188,755

MAGNETIC MICROSTRUCTURES FOR MAGNETIC RESONANCE IMAGING

The United States of Amer...

1. A magnetic resonance contrast agent comprising one or a plurality of contrast structures, wherein each contrast structure consists of a single wall consisting of a magnetic material arranged as a substantially cylindrical magnetic structure with a length-to-diameter ratio between 0.8 and 1.6, wherein each contrast structure has a maximum dimension between about 10 nm and about 100 ?m, wherein each contrast structure defines an axially extending hollow region therethrough, and wherein the hollow region encompasses a spatially extended region contained within a near-field region of the contrast structure over which the structure on its own or in conjunction within an applied magnetic field results in a substantially homogeneous field, such that nuclear magnetic moments of a second material when arranged within said spatially extended region precess at a characteristic Larmor frequency, whereby the magnetic resonance contrast agent, combined with the second material, induces a characteristic magnetic resonance signal of the magnetic material.
US Pat. No. 10,189,013

MONOLITHIC CATALYST COMPRISING MOLECULAR SIEVE MEMBRANE AND METHOD FOR PREPARING THE MONOLITHIC CATALYST

WUHAN KAIDI ENGINEERING T...

1. A method for preparing a monolithic catalyst comprising:cobalt;
a matrix, the matrix comprising at least one metal selected from the group consisting of silver, gold, copper, platinum, titanium, molybdenum, iron, and tin;
an additive, the additive being lanthanum, zirconium, cerium, rhodium, platinum, rhenium, ruthenium, titanium, magnesium, calcium, strontium, or a mixture thereof; and
a molecular sieve membrane, the molecular sieve membrane being mesoporous silica SBA-16 which is disposed on a surface of the metal matrix and is a carrier of the cobalt and the additive;
wherein
a thickness of the carrier of the molecular sieve membrane is between 26 and 67 ?m, the method comprising:
1) washing a plurality of metal matrixes having a honeycomb-shape and uniform sizes using deionized water; and drying the metal matrixes in an oven at 100° C.;
2) dissolving molecular sieve powders of the mesoporous silica SBA-16 in absolute ethanol to yield a mixture; oscillating the mixture for 20 to 30 min using an ultrasonic oscillation method to form a uniformly distributed soak solution of the molecular sieve powders; soaking the metal matrixes pretreated in 1) in the soak solution for 1 to 10 s; taking the metal matrixes out, and when the soak solution on the metal matrixes stops flowing and dripping down, soaking the metal matrixes in the soak solution again; repeating the impregnation of the metal matrixes, and then drying the metal matrixes in air;
3) placing the metal matrixes obtained in 2) in a molecular sieve solution of mesoporous silica SBA-16 and crystallizing the mesoporous silica SBA-16 for 5 to 120 hrs at a temperature of between 70 and 150° C. in a reaction still; allowing the mesoporous silica SBA-16 to grow in-situ on a surface of the metal matrixes to yield metal matrixes comprising a molecular sieve membrane; taking out the metal matrixes comprising the molecular sieve membrane, washing the metal matrixes comprising the molecular sieve membrane using deionized water, and drying; and roasting the metal matrixes comprising the molecular sieve membrane for 4 to 8 hrs at a temperature of between 400 and 600° C.; and
4) soaking the metal matrixes comprising the molecular sieve membrane obtained in 3) in a solution of a cobalt salt and the additive for 1 to 20 min; drying the metal matrixes comprising the molecular sieve membrane and aging at room temperature for 3 to 36 hrs; roasting the metal matrixes comprising the molecular sieve membrane for 6 to 12 hrs at a programmed temperature of between 300 and 550° C., and then gradually cooling the metal matrixes comprising the molecular sieve membrane to room temperature.
US Pat. No. 10,188,757

CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT

The General Hospital Corp...

1. A method for treating Alzheimer's disease in a subject in need thereof comprising the steps of:a) administering to the subject by oral inhalation a dry powder formulation consisting essentially of 17.1 mg of micronized cromolyn sodium, 12.8 mg lactose monohydrate, and 0.6 mg micronized magnesium stearate; and
b) administering orally to the subject 1 mg, 2 mg, 5 mg, 10 mg, or 25 mg of a non-steroidal anti-inflammatory drug,
wherein Alzheimer's Disease is treated in the subject.
US Pat. No. 10,190,039

SYNTHETIC ACID COMPOSITIONS ALTERNATIVES TO CONVENTIONAL ACIDS IN THE OIL AND GAS INDUSTRY

FLUID ENERGY GROUP LTD., ...

1. A synthetic acid composition for use in oil industry activities, said composition comprising:urea and hydrogen chloride in a molar ratio of not less than 0.1:1; and
a metal iodide or iodate.
US Pat. No. 10,189,271

NON-FOAMING AQUEOUS PARTICLE-FREE INKJET INK COMPOSITIONS

EASTMAN KODAK COMPANY, R...

1. An aqueous colorless particle-free inkjet ink composition that has a viscosity of less than 5 centipoises (0.005 N-sec) at 25° C., and comprises:an anionic polyether polyurethane having an acid number of at least 50 and an anionic acrylic polymer or anionic styrene-acrylic polymer having an acid number of at least 50; wherein the weight ratio of the anionic polyether polyurethane to the anionic acrylic polymer or anionic styrene-acrylic polymer is from 1:9 to and including 9:1, and the total amount of the anionic polyether polyurethane and the anionic acrylic polymer or anionic styrene-acrylic polymer is less than or equal to 20 weight % based on the total aqueous colorless particle-free inkjet ink composition weight, and
a defoamer that has a hydrophilic-lipophilic balance value of at least 3 and up to and including 5, which defoamer is present in an amount of at least 0.15 weight % and up to and including 1 weight %, based on the total aqueous colorless particle-free inkjet ink composition weight.
US Pat. No. 10,191,064

THYROGLOBULIN QUANTITATION BY MASS SPECTROSCOPY

Quest Diagnostics Investm...

1. A method for determining the amount of thyroglobulin in a test sample, comprising:(a) adding a thyroglobulin peptide standard in said test sample containing thyroglobulin peptides, wherein one or more valine of the thyroglobulin peptide standard is isotopically labeled with 13C, 15N;
(b) enriching said thyroglobulin peptides and thyroglobulin peptide standard from step (a);
(c) ionizing said thyroglobulin peptides and thyroglobulin peptide standard from step (b) to produce one or more thyroglobulin peptide ions and thyroglobulin peptide standard ions detectable by mass spectrometry; and
(d) detecting the amount of the ion(s) from step (c) by mass spectrometry; wherein the amount of the ion(s) detected in step (c) is related to the amount of thyroglobulin in said test sample and the amount of thyroglobulin peptide standard.
US Pat. No. 10,193,117

SEPARATOR FOR NONAQUEOUS SECONDARY BATTERY, AND NONAQUEOUS SECONDARY BATTERY

TEIJIN LIMITED, Osaka (J...

1. A separator for a nonaqueous secondary battery, comprising a porous substrate and an adhesive porous layer that is formed on at least one side of the porous substrate and contains a polyvinylidene-fluoride-based resin,the separator for a nonaqueous secondary battery being characterized in that the adhesive porous layer has a crystal size of 1 nm or more and 13 nm or less.
US Pat. No. 10,188,760

MODULATION OF IMMUNITY AND CEACAM1 ACTIVITY

1. A method for diagnosing a cancer in a human patient, said method comprising the step of contacting a biological sample derived from said patient with a CEACAM1 binding agent conjugated to a detectable moiety, wherein the CEACAM1 binding agent comprises a multimer agent consisting of at least two peptides selected from the group consisting of GYSWYK (SEQ ID NO:33), NRQII (SEQ ID NO:34), and QNDTG (SEQ ID NO: 35).
US Pat. No. 10,191,067

METHOD FOR IDENTIFYING AN AGENT FOR TREATING ABNORMAL KIDNEY FUNCTION

Proteomics International ...

1. A method of identifying an agent for treating or reducing the risk of developing abnormal kidney function, which is defined as an albumin creatinine ratio (ACR) of 3.5 or more, the method comprising:(i) contacting cells expressing at least one biomarker, wherein said at least one biomarker is CD5 antigen like, with a putative agent; and
(ii) comparing expression and/or levels of the at least one biomarker in the cells prior to contact with the putative agent to expression and/or levels of the at least one biomarker in the cells after contact with the putative agent;
wherein a change in the level or expression identifies the agent as an agent for treating or reducing the risk of developing abnormal kidney function.
US Pat. No. 10,191,068

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43

ARIZONA BOARD OF REGENTS ...

1. An antibody fragment comprising an amino acid sequence encoded by a nucleic acid, wherein the nucleic acid has at least 96% identity to SEQ ID NO:1.
US Pat. No. 10,190,045

NANO-COMPOSITE STRUCTURE AND PROCESSES MAKING OF

1. A nano-composite structure comprising a nano-composite material having an amorphous matrix with embedded nano-crystallites, wherein the amorphous matrix and the nano-crystallites are made of the same chemical elements, wherein the nano-composite structure exhibits no distinguishable crystalline grain boundaries between the amorphous matrix and the nano-crystallites, wherein the nano-composite structure comprises multiple layers of nano-composite material, the multiple layers of nano-composite material disposed one directly on top of another in direct contact, and wherein each of the nano-composite layers consists of the nano-composite material.
US Pat. No. 10,191,069

ACCURATE ASSAY MEASUREMENT OF HYDROPHOBIC HAPTENIC ANALYTES

Siemens Healthcare Diagno...

1. A method of determining an actual concentration of a hydrophobic haptenic analyte in an unknown sample suspected of containing the hydrophobic haptenic analyte, wherein the unknown sample is suspected of containing an interfering substance, the method comprising:(a) conducting a first assay method on an unknown sample to obtain a measured concentration of the hydrophobic haptenic analyte in the unknown sample and conducting a second assay method on the unknown sample to obtain a concentration of the interfering substance in the unknown sample, wherein the hydrophobic haptenic analyte is selected from the group consisting of fat-soluble vitamins, steroid hormones, therapeutic drugs, and drugs of abuse, and wherein the interfering substance is lipoproteins; and
(b) applying a predetermined correction formula that utilizes the measured concentration of the hydrophobic haptenic analyte and the measured concentration of the interfering substance obtained in step (a) to determine an actual concentration of the hydrophobic haptenic analyte in the unknown sample, wherein the correction formula is predetermined by a method that comprises:
(i) measuring a concentration of the hydrophobic haptenic analyte for at least two different samples using the first assay method and measuring the concentration of the hydrophobic haptenic analyte for the at least two different samples using a reference method wherein the samples also comprise the interfering substance,
(ii) determining a bias between the first assay method and the reference method wherein the bias is the difference between the concentration of the hydrophobic haptenic analyte determined by the reference method and the first assay method for each different sample;
(iii) measuring a concentration of the interfering substance for the at least two different samples; and
(iv) determining the correction formula by conducting a regression analysis using the bias and the concentration of the interfering substance for each of the at least two different samples,wherein the regression analysis comprises forming a regression line and using the slope and intercept of the regression line to form the following correction formula:[An]=[mAn]+(a×[mIS]+b)wherein:[An] is the actual concentration of the hydrophobic haptenic analyte in the unknown sample,
[mAn] is the measured concentration of the hydrophobic haptenic analyte in the unknown sample,
[mIS] is the measured concentration of the interfering substance in the unknown sample,
a is the slope of the regression line, and
b is the intercept of the regression line; wherein the first assay method is an immunoassay method and wherein the reference method directly measures a character specific to the analyte and is different from the first assay method.
US Pat. No. 10,191,070

METHODS AND SYSTEMS FOR MEASURING SEROTONIN IN A SAMPLE

Laboratory Corporation of...

1. A method for determining amount of released serotonin in a sample, the method comprising:providing a sample comprising a biological sample, donor platelets, and heparin;
incubating the sample for a period of time to release serotonin from the donor platelets;
chromatographically separating serotonin from other components in the incubated sample using liquid chromatography; and
analyzing the chromatographically separated serotonin by mass spectrometry to determine the amount of released serotonin in the sample relative to a total amount of serotonin available in the donor platelets.
US Pat. No. 10,189,792

METHOD AND APPARATUS FOR SYNTHESIZING A WATER-SOLUBLE HEXAARYL BIIMIDAZOLE

1. A method for forming a water-soluble hexaaryl biimidazole, comprising the steps of:a) reacting benzil with a carboxy benzaldehyde and ammonium acetate to yield a carboxy triaryl imidazole; and
b) dimerizing said carboxy triaryl imidazole in an alkaline aqueous solution of potassium ferricyanide to yield a water-soluble salt of a bicarboxy hexaaryl biimidazole,
wherein said water-soluble salt of a bicarboxy hexaaryl biimidazole is the disodium salt of 2,2?-bicarboxy hexaaryl biimidazole.
US Pat. No. 10,188,772

DRUG DELIVERY MEDICAL DEVICE

Micell Technologies, Inc....

1. A medical device comprising:a balloon; and
a coating on at least a portion of the balloon,
wherein the coating comprises smooth and spherical particles having rapamycin particles encapsulated in a first polymer material prior to inclusion in the coating, the particles being from about 0.5 ?m to about 10 ?m in size and the first polymer being PLGA, and
wherein each particle is at least partially encapsulated in a second polymer material in the coating.
US Pat. No. 10,188,773

COMPOSITIONS AND DEVICES OF POLY-4-HYDROXYBUTYRATE

Tepha, Inc., Lexington, ...

1. A composition comprising a polyhydroxyalkanoate (PHA) polymer obtained by a process comprising: suspending a PHA polymer biomass in ethanol for a period of time effective to extract lipids into the ethanol, separating the PHA polymer biomass from the ethanol by solid-liquid separation, collecting the ethanol-washed biomass, and extracting the PHA polymer into a solvent.
US Pat. No. 10,193,132

SYNTHESIS OF SUBMICROMETER TO MICROMETER-SIZED CATHODE MATERIALS

Washington University, S...

1. A method of producing submicrometer- to micrometer-sized, spherical-shaped cathode materials for lithium ion batteries, the method comprising:dissolving a lithium salt and a metal salt in water, alcohol, oil or a mixture of any two or more thereof, forming a lithium metal precursor solution,
spraying the precursor solution to form fine aerosolized droplets,
flowing the aerosolized droplets in a carrier medium into a pyrolysis hydrogen flame producing submicrometer- to micrometer-sized spherical lithium-metal-oxide particles in a range of from about 0.1 ?m to about 100 ?m, wherein no external heat source is required, and wherein the droplets are flowing in an environment having a temperature of less than 1200° C., wherein the submicrometer- to micrometer-sized spherical-shaped lithium-metal-oxide particles produced have a formula of Li?M??O? wherein ? is 0???1; ? is 0???2; and ? is 0???4; and wherein M? is selected from the group consisting of Ni, Co, Mn, Al, Mg, Fe, Cu, Zn, V, Mo, Nb, Cr, Si, Ti, Zr, and a mixture of any two or more thereof.
US Pat. No. 10,188,774

METHOD FOR PRODUCING ANTITHROMBOTIC COATING MATERIAL

TERUMO KABUSHIKI KAISHA, ...

1. A method for producing an antithrombotic coating material, the method comprising:preparing a methanol solution containing a monomer consisting of methoxymethyl acrylate, methoxyethyl acrylate (MEA), ethoxymethyl acrylate, ethoxyethyl acrylate, methoxymethyl methacrylate, methoxyethyl methacrylate, ethoxymethyl methacrylate, ethoxyethyl methacrylate, or a combination thereof;
adding a radical polymerization initiator having a 10-hour half-life temperature of 60° C. or less to the methanol solution to prepare a polymerization reaction liquid, wherein the radical polymerization initiator having a 10-hour half-life temperature of 60° C. or less is 2,2?-azobis(4-methoxy-2,4-dimethylvaleronitrile); and
polymerizing the monomer to form a polymer, wherein the monomer used to form the polymer consists of methoxymethyl acrylate, methoxyethyl acrylate (MEA), ethoxymethyl acrylate, ethoxyethyl acrylate, methoxymethyl methacrylate, methoxyethyl methacrylate, ethoxymethyl methacrylate, ethoxyethyl methacrylate, or a combination thereof.
US Pat. No. 10,193,134

DOPED SODIUM MANGANESE OXIDE CATHODE MATERIAL FOR SODIUM ION BATTERIES

UMICORE, Brussels (BE) U...

1. A sodium transition metal cathode material for a rechargeable sodium battery, having a P2 layered bronze crystal structure and having a composition NaxMO2, M comprising at least 55 mol % manganese, wherein the manganese valence state is at least 3.75, wherein 2/3
US Pat. No. 10,193,138

GLASS-FIBER CONTAINING COMPOSITE MATERIALS FOR ALKALI METAL-BASED BATTERIES AND METHODS OF MAKING

Johns Manville, Denver, ...

1. A method of making a glass-fiber composite, the method comprising the steps of:forming a wet laid non-woven glass fiber substrate, wherein the glass fiber substrate comprises a sodium-based compound selected from the group consisting of NaMnO2; NaNiO2; Na(Ni0.5Mn0.5)O2, NaFePO4, Na2Fe2(SO4)3, and Na2Mn11[Mn11(CN)6]; and contacting alkali-metal containing particles on the substrate.
US Pat. No. 10,193,141

POSITIVE ELECTRODE MIXTURE AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY

TODA KOGYO CORPORATION, ...

1. A positive electrode mixture comprising carbon black having a bulk density of not more than 0.1 g/cm3, a crystallite size of 10 to 40 ?, an iodine adsorption of 1 to 150 mg/g, a volatile content of not more than 0.1% and a metal impurity content of not more than 20 ppm, and a positive electrode (cathode) active substance having an operating voltage or an initial crystal phase transition voltage of not less than 4.5 V on the basis of lithium.
US Pat. No. 10,188,783

METHOD FOR EXTRACORPOREAL REMOVAL OF PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD

ExThera Medical Corporati...

1. A method for extracorporeal removal of a virus from a subject, said method comprising:a) contacting said subject's whole blood with heparin immobilized on a solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said virus in said subject's whole blood sample to the heparin;
b) separating the whole blood from the solid substrate;
c) recovering said whole blood containing a reduced amount of said virus; and
d) reintroducing into said subject said whole blood containing a reduced amount of said virus.
US Pat. No. 10,189,808

SOLID FORMS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES

Celgene Corporation, Sum...

1. A solid form of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a tautomer thereof, which is Form C having an X-ray powder diffraction pattern comprising peaks at about 16.7, 16.9, 17.7 or 24.7 degrees 2?.
US Pat. No. 10,193,143

NEGATIVE ELECTRODE ACTIVE MATERIAL FOR ELECTRICITY STORAGE DEVICES AND METHOD FOR PRODUCING SAME

NIPPON ELECTRIC GLASS CO....

1. A negative electrode active material for an electricity storage device, comprising a composition containing TiO2, Na2O, and a network-forming oxide, and comprising a precipitated crystal of a monoclinic crystal containing Na, Ti, and O.
US Pat. No. 10,193,144

HIGH CAPACITY LITHIUM ION BATTERIES HAVING OXIDES, PEROXIDES, OR SUPEROXIDES AS CATHODE ACTIVE MATERIAL

UCHICAGO ARGONNE, LLC, C...

1. A cathode comprising an electroactive material comprising LO2 or L2O2, wherein each L is independently selected from Li, Na, K, Be, Mg, Ca, and Al; the electroactive material is metal-coated, metal oxide-coated, or doped; the electroactive material has less than or equal to 10 wt. % of transition metal catalyst; and the electroactive material is non-cycled active material, wherein the electroactive material is doped with Li, Na, K, Be, Mg, Ca, Al, Cu, Mn, Nd, Ag, Ti, Ni, Cd, Ir, Ta, Y, Zr, Nb, Rh, or Cr.
US Pat. No. 10,189,811

METHOD FOR PREPARING THE ANHYDROUS CRYSTALLINE FORM OF ISONIAZID-DERIVED HYDRAZONE, THUS PRODUCED CRISTALLINE POLYMORPH OF THE ANHYDROUS FORM, USE THEREOF FOR THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSONISM AND OTHER NEURODEGENERATIVE DISORDERS, AND PH


US Pat. No. 10,190,071

STABILIZED BLENDS CONTAINING FRICTION MODIFIERS

The Lubrizol Corporation,...

1. A composition comprising:(a) a medium comprising a solvent, a functional fluid, an additive concentrate or combinations thereof; and
(b) a friction modifier component comprising a condensation product of tartaric and/or citric acid and a linear or branched fatty alcohol of 10 to 18 carbon atoms wherein said condensation product is not fully soluble in the medium; and
(c) a stabilizing component comprising a dispersant that is soluble in (a) and that interacts with (b) such that the solubility of (b) in (a) is improved, wherein said stabilizing component is present at about 4% to about 8% by weight of said composition;
wherein component (b) is present in component (a) in the form of dispersed particles wherein no more than 10 percent by weight of the particles have a diameter of more than 0.5 microns;
wherein component (b) is present in the overall composition at a level of 2 to 4 percent by weight;
wherein component (c), the stabilizing component, comprises: (i) a nitrogen-containing dispersant comprising a reaction product of a hydrocarbyl-substituted succinic acylating agent and a polyamine; (ii) a borated nitrogen-containing dispersant comprising a reaction product of a hydrocarbyl-substituted succinic acylating agent and a polyamine which is borated; (iii) an alkyl imidazoline derived from a polyalkylene amine and a fatty mono-carboxylic acid; or combinations thereof;
wherein a N:CO ratio of (i) or (ii) ranges from greater than 1.3:1 to about 2:1; and
wherein a TBN, as defined by ASTM D4739, of (iii) is greater than 9.
US Pat. No. 10,190,072

METHOD FOR IMPROVING ENGINE FUEL EFFICIENCY

EXXONMOBIL RESEARCH AND E...

1. A method for improving fuel efficiency and reducing frictional properties, while maintaining or improving deposit control, in an engine lubricated with a lubricating oil by using as the lubricating engine oil a formulated oil, said formulated oil having a composition comprising:from 75 to 95 wt % of lubricating oil base stock selected from the group consisting of a Group I base stock, a Group II base stock, a Group III base stock, a Group IV base stock, a Group V base stock and combinations thereof;
a friction modifier mixture comprising a polymeric ethoxylated fatty acid ester having a molecular weight of greater than or equal to 2000 at from 0.1 to 1.0 wt. % of the weight of the lubricating engine oil and an organic molybdenum containing friction modifier contributing from 80 ppm to 500 ppm of elemental molybdenum based on the weight of the lubricating engine oil, and
an overbased calcium salicylate detergent contributing from 200 ppm to 2000 ppm of elemental calcium based on the weight of the lubricating engine oil;
wherein the remainder of the lubricating engine oil includes one or more other lubricating oil additives;
wherein fuel efficiency and friction reduction properties are improved (mini-traction machine (MTM) in Stribeck mode friction coefficient at 140° C. less than or equal to 0.20) and deposit control is maintained or improved (TEOST 33C total deposits less than or equal to 30 mg) as compared to friction reduction properties and deposit control achieved using the same lubricating engine oil not containing the friction modifier mixture and the overbased calcium salicylate detergent.
US Pat. No. 10,190,074

COMPOSITION COMPRISING CHOLESTEROL

GOLDEN OMEGA S.A., Las C...

1. A process for producing a composition comprising at least 20% by weight of cholesterol, based on 100% total weight of the composition, the process comprising the steps of:(a) distilling a fish oil having at most 2% by weight of free fatty acids, based on 100% total weight of the fish oil, in an admixture with an auxiliary fluid in a vacuum distillation column to obtain a first distillate and a first residue; and
(b) distilling the first distillate in a vacuum distillation column to obtain a second distillate and a second residue, wherein (i) the second residue comprises the composition comprising at least 20% by weight cholesterol, based on the total weight of the composition, and (ii) the composition has a lower content of anthropogenic contaminants than the fish oil.
US Pat. No. 10,188,793

INSULIN ON BOARD CALCULATION, SCHEDULE AND DELIVERY

Bigfoot Biomedical, Inc.,...

1. An insulin delivery system comprising:an insulin delivery device configured to deliver insulin to a user of the system; and
a computer-based control unit associated with the insulin delivery device, the computer-based control unit having a computer-based processor, wherein the computer-based processor is configured to:
calculate a relative insulin on board value for a specific time by calculating a first value that represents a reference insulin on board value at the specific time, calculating a second value that represents an automated insulin on board value at the specific time, and subtracting one of the first and second values from the other;
determine a future insulin delivery schedule over a period of time based in part on the calculated relative insulin on board value; and
configure the insulin delivery device to deliver insulin according to the determined future insulin delivery schedule, and
wherein the automated insulin on board value represents at least one insulin delivery automatically specified by the computer-based control unit.
US Pat. No. 10,189,818

5-(5-(2-(3-AMINOPROPDOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITFILE (S)-LACTATE MONOHYDRATE

Eli Lilly and Company, I...

1. A compound which is 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile (S)-lactate monohydrate.
US Pat. No. 10,192,641

METHOD OF GENERATING A DYNAMIC PATHWAY MAP

The Regents of the Univer...

1. A processor-based method of generating a dynamic pathway map (DPM), comprising:accessing a model database that stores a probabilistic pathway model that comprises a plurality of pathway elements;
assigning an influence level for at least one pathway of a first number of the plurality of pathway elements on the basis of known attributes;
cross correlating the first number of the plurality of pathway elements;
assigning an influence level for at least one pathway on the basis of assumed attributes;
measuring a patient sample to identify measured attributes of the patient sample, based on a genome-scale assay;
modifying the probabilistic pathway model by using a plurality of the measured attributes for a plurality of elements of the patient sample, via an analysis engine, the modifying comprising:
obtaining a factor graph representing states of entities in a cell and interactions between the entities, wherein the factor graph encodes a state of the cell using a random variable for each entity and wherein the factor graph has reference pathway activity information for a particular pathway, the reference pathway indicating deviations from the probabilistic pathway model; and
formulating a treatment option for the patient based on the reference pathway activity of the factor graph, wherein at least one of the above method operations is performed through a processor.
US Pat. No. 10,191,365

REFLECTIVE MASK BLANK, METHOD OF MANUFACTURING REFLECTIVE MASK BLANK, REFLECTIVE MASK AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Shinju...

1. A reflective mask blank, comprising:a mask blank multilayer film that comprises a multilayer reflective film obtained by alternately laminating a high refractive index layer and a low refractive index layer, and
an absorber film on or above a main surface of a mask blank substrate;
wherein, the root mean square roughness (Rms), obtained by measuring a 3 ?m ×3 ?m region on a surface of the reflective mask blank on which the mask blank multilayer film is formed with an atomic force microscope, is not more than 0.5 nm and an integrated value of a power spectrum density at a spatial frequency of 1 ?m?1 to 10 ?m?1 is not more than 800×10?3 nm3.
US Pat. No. 10,190,086

METHODS OF PITCHING YEAST FOR FERMENTATION, AND RELATED METHODS OF FERMENTATION AND SYSTEMS

POET Research, Inc., Sio...

1. A method of pitching yeast for fermentation, the method comprising:providing a first aqueous composition in a first fermentation reactor, wherein the first aqueous composition comprises:
yeast;
a slurry comprising water and a processed plant material comprising an amount of at least one monosaccharide; wherein the processed plant material comprises corn flour and the slurry further comprises one or more enzymes that can break down starch in the corn flour into glucose;
fermenting the first aqueous composition in the first fermentation reactor to form a first beer composition comprising alcohol;
providing a fraction of the first beer composition to a second fermentation reactor, wherein the first beer composition in the first fermentation reactor comprises an alcohol at a concentration of at least 15 percent by volume when the fraction of the first beer composition is removed from the first fermentation reactor, and wherein the fraction of the first beer composition comprises a fraction of the yeast and the alcohol;
combining a slurry with the fraction of the first beer composition in the second fermentation reactor to form a second aqueous composition in the second fermentation reactor, wherein the slurry comprises water and a processed plant material comprising an amount of at least one monosaccharide; wherein the processed plant material comprises corn flour and the slurry further comprises one or more enzymes that can break down starch in the corn flour into glucose; and
distilling the first beer composition from the first fermentation reactor to recover alcohol.
US Pat. No. 10,191,366

ETCH VARIATION TOLERANT OPTIMIZATION

ASML Netherlands B.V., V...

1. A method to improve a lithographic process for imaging a portion of a design layout onto a substrate using a lithographic projection apparatus and for transferring the imaged portion of the design layout to the substrate by an etching process, the method comprising:determining a value of an evaluation point of the lithographic process for each of a plurality of variations of the etching process;
computing, by a hardware computer system, a multi-variable cost function of a plurality of design variables that are characteristics of the lithographic process, wherein the multi-variable cost function is a function of a deviation from the determined values of the evaluation point; and
reconfiguring one or more of the characteristics of the lithographic process by adjusting one or more of the design variables and re-evaluating the cost function, until a termination condition for the cost function is satisfied.
US Pat. No. 10,190,091

METHODS OF CELL SEPARATION

CELLS 4 LIFE GROUP LLP, ...

1. A method for separating cells, said method comprising:(a) contacting a blood cell-containing sample containing erythrocyte blood cells with:
(i) a macromolecular erythrocyte sedimentation enhancer, and
(ii) dimethyl sulphoxide (DMSO), dimethylglycine (DMG) and/or valine;
(b) allowing said sample to partition into a sedimented phase and a supernatant phase; and
(c) recovering non-erythrocyte blood cells from said supernatant phase;
wherein in step (a), when the sample is contacted with components (i) and (ii), the resulting mixture comprises component (i) at a concentration of 0.01 to 10% w/v, and component (ii) at a concentration of 0.01 to 10% w/v.
US Pat. No. 10,191,371

UNDERLAYER COMPOSITION AND METHOD OF IMAGING UNDERLAYER

ROHM AND HAAS ELECTRONIC ...

1. An underlayer comprising:an acid sensitive copolymer comprising:
an acid decomposable group;
an attachment group; and
a functional group; and
a photoacid generator,
where the functional group is operative to adjust neutrality of the acid-sensitive copolymer relative to a self-assembling block copolymer that is to be disposed on the underlayer, where the neutrality means that a surface energy of the underlayer is substantially the same as that of at least one block of the block copolymer;
wherein the attachment group is covalently bonded to a hydrophilic surface of a substrate by alkoxide linkages where the attachment group comprises a thiol, a primary or secondary amine substituted, a straight chain or branched C1-30 alkyl, a C3-30 cycloalkyl, a C6-30 aryl, a C7-30 alkaryl, a C7-30 aralkyl, a C1-30 heteroalkyl, a C3-30 heterocycloalkyl, a C6-30 heteroaryl, a C7-30 heteroalkaryl, a C7-30 heteroaralkyl, or a combination comprising at least one of these groups; and wherein the acid decomposable groups are ester groups, acetal groups, ketal groups, or pyrocarbonate groups.
US Pat. No. 10,190,092

PROCUREMENT OF PLACENTAL STEM CELLS

1. A method for collecting stem cells from a placenta obtained after childbirth, the method comprising:draining cord blood from the placenta obtained after childbirth;
collecting the drained cord blood in a first collection;
infusing the drained placenta with a first solution, the first solution consisting of a placental preservative base solution and prostaglandin, wherein the placental preservative base solution consists of NaCl, KCl, glucose, citric acid, adenine, histidine, glutamate, glutathione, and N-acetyl-L-cysteine;
infusing the placenta with a second solution before the first solution is collected, the second solution consisting of said placental preservative base solution, a stem cell releasing agent, an antibiotic, and an anticoagulant, wherein the stem cell releasing agent is 1, 1?-[1,4-phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane or a pharmaceutically acceptable salt thereof;
waiting for a predetermined amount of time as the first and second solutions perfuse the placenta, wherein said predetermined amount of time is 5 minutes or fewer; and
collecting, in a second collection, said first and second solutions from the placenta, wherein the collected first and second solutions comprise stem cells from the placenta.
US Pat. No. 10,190,093

ARTIFICIAL OOCYTE ACTIVATION

The Curators of the Unive...

1. A method of activating an unfertilized porcine oocyte comprising decreasing intracellular Zn2+ concentration of the oocyte by contacting the oocyte with a Zn2+ binding moiety comprising approximately 200 mM TPEN (N,N,N?,N?-tetrakis(2-pyridylmethyl)ethane-1,2-diamine), and increasing intracellular Ca2+ concentration of the oocyte prior to decreasing the intracellular Zn2+ concentration of the oocyte, wherein the intracellular Ca2+ concentration of the oocyte is not increased in an amount sufficient to induce oocyte activation, and wherein said contacting results in activating the oocyte.
US Pat. No. 10,191,373

METHOD FOR PRODUCING POLYMER

SHIN-ETSU CHEMICAL CO., L...

1. A method for producing a polymer comprising recurring units having an acid generator bound to the backbone, comprisingpolymerizing monomers corresponding to the recurring units in a solution of a non-polymerizable compound containing at least one nitrogen atom to which at least one acid labile group is bound.
US Pat. No. 10,189,837

CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT

Medivation Technologies L...

4. A pharmaceutical composition comprising the crystalline tosylate salt of claim 1 and a pharmaceutically acceptable excipient.
US Pat. No. 10,190,094

METHODS AND COMPOSITIONS RELATED TO INDUCED SENSORY NEURONS

The Scripps Research Inst...

1. A method for generating induced sensory neurons (iSNs), comprising co-expressing Brn3A and Ngn1 genes via one or more expression vectors harboring Brn3A and Ngn1 genomic or cDNA sequences in a non-neuronal cell, thereby generating induced sensory neurons, wherein the non-neuronal cell is a fibroblast or a stem cell from a mammal.
US Pat. No. 10,193,171

FUEL CELL WITH INTEGRATED WATER MANAGEMENT LAYER AND FABRICATION METHOD THEREOF

1. Fabrication method of a fuel cell comprising the following successive steps:providing a substrate comprising:
at least one membrane-electrode assembly, formed by an electrolytic membrane arranged between a first electrode and a second electrode,
a first current collector arranged on the first electrode,
depositing a fluoropolymer solution on the first current collector,
making a solvent of the fluoropolymer solution evaporate so as to form a porous thin layer of fluoropolymer.
US Pat. No. 10,190,095

MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS

Cornell Research Foundati...

1. An in vitro method of obtaining human oligodendrocyte progenitor cells, said method comprising:providing a mixed population containing human brain or spinal cord cell types;
removing neurons and neuronal progenitor cells expressing polysialylated N-CAM (PSA-NCAM) from the mixed population to produce a treated mixed population; and
removing the oligodendrocyte progenitor cells expressing A2B5 from the treated mixed population to form an enriched population of A2B5+/PSA-NCAM? oligodendrocyte progenitor cells.
US Pat. No. 10,190,096

METHODS FOR GENERATING STEM CELL-DERIVED ? CELLS AND USES THEREOF

President and Fellows of ...

1. A method for generating stem cell-derived ? (SC-?) cells, the method comprising contacting a cell population comprising endocrine progenitor cells under conditions suitable to direct differentiation of said endocrine progenitor cells into said SC-? cells with an effective amount of an agent that decreases the level and/or activity of c-Jun N-terminal kinase (JNK), thereby generating said SC-? cells, wherein the endocrine progenitor cells comprise PDX1+/NKX6.1+/NEUROD1+/insulin+/glucagon?/somatostatin? cells.
US Pat. No. 10,190,097

METHOD AND COMPOSITION FOR INDUCING HUMAN PLURIPOTENT STEM CELLS

The Regents of the Univer...

1. A method of pluripotency reprogramming, comprising:treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and
changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms;
wherein the FreP cell expresses NANOG and does not form teratoma, and
wherein the human cell is a fibroblastic cell.
US Pat. No. 10,190,098

AAV VECTORS PRODUCED BY INSECT CELLS COMPRISING REP52 AND REP78 CODING SEQUENCES WITH DIFFERENTIAL CODON BIASES

UniQure IP B.V., Amsterd...

1. A recombinant adeno-associated virus (rAAV) virion obtainable by culturing an insect cell under conditions such that rAAV virions are produced and recovering the rAAV virions, wherein the insect cell comprises a baculoviral vector comprising:(i) a first nucleotide sequence encoding a first amino acid sequence of an AAV Rep52 protein selected from the group consisting of:
(a) a sequence of at least 85% identity with SEQ ID NO: 10;
(b) a nucleotide sequence complementary to the full length sequence of (a); and
(c) a nucleotide sequence that differs from the sequence of (a) due to degeneracy of the genetic code; and
(ii) a second nucleotide sequence encoding a second amino acid sequence of an AAV Rep78 protein;
(iii) a third nucleotide sequence comprising two AAV inverted terminal repeat (ITR) sequences and a nucleotide sequence encoding a gene product of interest located between the two AAV ITR sequences; and,
(iv) a fourth nucleotide sequence comprising AAV capsid protein-coding sequences operably linked to expression control sequences for expression in an insect cell;
wherein the first and the second amino acid sequences share at least 90% sequence identity in a region from the second amino acid residue to the C-terminal residue of the AAV Rep52 protein, and
wherein a portion of the first nucleotide sequence and a portion of the second nucleotide sequence that encode the region from the second amino acid residue to the C-terminal residue of the AAV Rep52 protein each comprise one or more contiguous stretches of at least 300 nucleotides that are less than 90% identical.
US Pat. No. 10,192,661

R—T—B BASED SINTERED MAGNET

TDK CORPORATION, Tokyo (...

1. A R-T-B based sintered magnet, wherein:R contains Y and R1,
Y is yttrium,
R1 is at least one rare earth element except Y but contains Nd, and
T represents at least one transition metal element containing Fe or a combination of Fe and Co,
a ratio of R1 to Y (R1:Y) in a grain boundary phase is 73:27 to 55:45 in terms of a calculated molar ratio of the grain boundary phase.
US Pat. No. 10,190,099

IBV STRAINS AND USES THEREOF

BIOMUNE COMPANY, Lenexa,...

1. A method for protecting or vaccinating poultry against infectious bronchitis virus, comprising orally administering to said poultry an attenuated infectious bronchitis virus (IBV), wherein said attenuated IBV comprises a S1 gene having a nucleotide sequence with at least 98% identity to SEQ ID NO: 1, and wherein said attenuated IBV is formulated in gel drops.
US Pat. No. 10,190,102

LACCASE VARIANTS WITH IMPROVED PROPERTIES

METGEN OY, Kaarina (FI)

1. A polypeptide with laccase activity comprising an amino acid sequence that is at least 94% identical to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 31-61, wherein the polypeptide comprises a non-polar amino acid residue selected from the group consisting of methionine, leucine, isoleucine, valine, proline, glycine, and phenylalanine at an amino acid position corresponding to position 113 in SEQ ID NO: 1.
US Pat. No. 10,188,052

MAIZE PLANTS WITH IMPROVED PATHOGEN RESISTANCE

Monsanto Technology LLC, ...

1. A method of obtaining a corn plant with improved tar spot complex (TARSC) resistance, said method comprising:a) providing a population of corn plants;
b) obtaining at least one DNA sample from at least one plant within said population;
c) detecting in the DNA sample the presence of a TARSC resistance allele comprising a “T” at nucleotide position 61 of SEQ ID NO: 6 in, or genetically linked to, a chromosomal segment between about 3.99 cM and about 17.7 cM on chromosome 10;
d) selecting one or more plants from said population based on the presence of said allele;
e) crossing at least one selected plant comprising said allele with a second corn plant that comprises one or zero TARSC resistance alleles to produce one or more progeny plants that produce seeds;
f) collecting the seeds produced by the one or more progeny plants; and
g) growing from said seeds at least one plant having said allele and having improved TARSC resistance.
US Pat. No. 10,190,103

POLYPEPTIDES HAVING GLUCURONYL ESTERASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

1. A method for degrading or hydrolyzing a cellulosic material, comprising: contacting the cellulosic material with an enzyme composition and an isolated polypeptide having glucuronyl esterase activity to thereby degrade or hydrolyze the cellulosic material, wherein the isolated polypeptide having glucuronyl esterase activity is selected from the group consisting of:(a) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of amino acids 101 to 474 of SEQ ID NO: 2;
(b) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions with the full-length complement of the nucleotide sequence of nucleotides 33 to 1457 of SEQ ID NO: 1, wherein the high stringency conditions are defined as prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, and washing three times each for 15 minutes using 2×SSC, 0.2% SDS at 65° C.;
(c) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of nucleotides 33 to 1457 of SEQ ID NO: 1; and
(d) a fragment of the amino acid sequence of amino acids 101 to 474 of SEQ ID NO: 2, wherein the fragment has glucuronyl esterase activity.
US Pat. No. 10,188,054

HYBRID TOMATO VARIETY 72-191 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum plant designated 72-191 RZ, representative seed of which having been deposited under NCIMB Accession No. 42733.
US Pat. No. 10,189,080

METHOD FOR PRODUCING AN ENGINE COMPONENT, ENGINE COMPONENT, AND USE OF AN ALUMINIUM ALLOY

Federal-Mogul Nurnberg, ...

1. A method of producing an engine component by gravity die casting,wherein an aluminium alloy is cast consisting of the following alloy elements:
Silicon: 9% by weight to ?10.5% by weight,
Nickel: >2.0% by weight to <3.5% by weight,
Copper: >3.7% by weight to 5.2% by weight,
Cobalt: to <1% by weight,
Magnesium: 0.5% by weight to 1.5% by weight,
Iron: 0.1% by weight to 0.7% by weight,
Manganese: 0.1% by weight to 0.4% by weight,
Zirconium: >0.1% by weight to <0.2% by weight,
Vanadium: >0.1% by weight to <0.2% by weight,
Titanium: 0.05% by weight to <0.2% by weight,
Phosphorus: 0.004% by weight to 0.008% by weight,
with aluminium and unavoidable impurities constituting the rest.
US Pat. No. 10,190,105

HBV POLYMERASE MUTANTS

Transgene S.A., Illkirch...

1. A mutant polypeptide which comprises a mutated HBV polymerase domain with an internal deletion that functionally disrupts the polymerase activity, wherein said internal deletion is of at least 4 amino acid residues and at most 30 amino acid residues, wherein said mutated polymerase domain comprises the amino acid sequence shown in SEQ ID NO:1 but lacks at least the Tyr residue in position 203, the Met residue in position 204, the Asp residue in position 205 and the Asp residue in position 206, the Val residue in position 207, the Val residue in position 208, and the Leu residue in position 209.
US Pat. No. 10,188,055

WATERMELON LINE ACE PLUS

SAKATA SEED AMERICA, INC....

1. A seed of watermelon line Ace Plus, wherein a representative sample of seed of said line was deposited under ATCC Accession No. PTA-125206.
US Pat. No. 10,190,106

CAS9-DNA TARGETING UNIT CHIMERAS

Univesity of Massachusett...

1. A fusion protein comprising an attenuated Streptococcus pyogenes Cas9 (SpCas9) nuclease, said nuclease comprising a protospacer adjacent motif recognition domain having a lysine-substituted or serine substituted arginine residue and a DNA binding domain (DBD) protein.
US Pat. No. 10,193,183

NONAQUEOUS ELECTROLYTE SECONDARY BATTERIES

SANYO Electric Co., Ltd.,...

1. A nonaqueous electrolyte secondary battery comprising a positive electrode including a lithium transition metal oxide, a negative electrode including a negative electrode active material capable of storing and releasing lithium ions, and a nonaqueous electrolyte,the negative electrode active material including a carbon material as a main component,
the negative electrode including a lithium tungsten composite oxide and/or a lithium molybdenum composite oxide.
US Pat. No. 10,188,056

HYBRID TOMATO VARIETY 72-762 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum tomato plant designated 72-762 RZ, representative seed of which having been deposited under NCIMB Accession No. 42810.
US Pat. No. 10,188,057

SOYBEAN CULTIVAR CL1462431

Syngenta Participations A...

1. A plant, a plant part, or a seed of soybean variety CL1462431, wherein a representative sample of seed of said soybean variety CL1462431 has been deposited under ATCC Accession Number PTA-123834.
US Pat. No. 10,190,108

METHOD FOR REDUCING VISCOSITY IN SACCHARIFICATION PROCESS

DANISCO US INC., Palo Al...

1. A biomass saccharification mixture comprising:a. a pretreated biomass material; and
b. a non-naturally occurring enzyme composition comprising a glycosyl hydrolase family 61 (“GH61”) polypeptide having GH61/endoglucanase activity, wherein the GH61 polypeptide
i) has at least 65% in sequence identity to residues 22-344 of SEQ ID NO:27; or
ii) is encoded by a polynucleotide sequence or a complement thereof that has at least 65% sequence identity to SEQ ID NO:30; or
iii) is encoded by a polynucleotide sequence that hybridizes under high stringency conditions to a sequence that is complementary to SEQ ID NO:30;
wherein the enzyme composition is a whole cellulase comprising at least one polypeptide having cellobiohydrolase activity, at least one polypeptide having endoglucanase activity that is different from the GH61 polypeptide, and at least one polypeptide having beta-glucosidase activity and wherein the whole cellulase is derived from a host cell containing a heterologous expression cassette comprising a nucleic acid encoding the GH61 polypeptide, wherein the GH61 polypeptide is present in the whole cellulase in an amount of at least 6 wt % and no more than 50 wt % based on the total weight of protein in the whole cellulase and wherein said biomass saccharification mixture has a lower viscosity than a biomass saccharification mixture without the GH61 polypeptide and/or is capable of increasing the level of saccharification in the mixture as compared to the level of saccharification in a mixture having no or a lower level of GH-61 polypeptide.
US Pat. No. 10,188,058

SWEET CORN HYBRID SVSK6143 AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A corn plant comprising at least a first set of the chromosomes of corn line SHY-6S15-9078LP or corn line SHY-6RHBE322, a sample of seed of said lines having been deposited under ATCC Accession Number PTA-124211 and ATCC Accession Number PTA-124212, respectively.
US Pat. No. 10,190,109

METHODS FOR OBTAINING POSITIVE TRANSFORMANTS OF A FILAMENTOUS FUNGAL HOST CELL

Novoyzmes, Inc., Davis, ...

1. A filamentous fungal host cell, comprising: a tandem construct comprising (i) one or more selectable markers, (ii) a first polynucleotide encoding a first polypeptide having biological activity operably linked to a first promoter and a first terminator, and (iii) a second polynucleotide encoding a second polypeptide having biological activity operably linked to a second promoter and a second terminator, wherein the tandem construct integrated by ectopic integration into the chromosome of the filamentous fungal host cell, wherein the tandem construct further comprises a first homologous repeat flanking 5? of the one or more selectable markers and a second homologous repeat flanking 3? of the one or more selectable markers, wherein the first homologous repeat and the second homologous repeat undergo homologous recombination to excise the one or more selectable markers, and wherein upon the excision of the one or more selectable markers, the one or more selectable markers can be reused for introducing another tandem construct into the filamentous fungal host cell.
US Pat. No. 10,188,059

SOYBEAN VARIETY 5PUWT62

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 5PUWT62, wherein a sample of seed of said variety has been deposited under ATCC Accession No. PTA-125158.
US Pat. No. 10,190,110

ENGINEERED BOTULINUM NEUROTOXIN

PRESIDENT AND FELLOWS OF ...

1. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B, wherein the modified receptor binding domain comprises an amino acid substitution of M, Q, T or I at the amino acid position E1191 of the polypeptide of SEQ ID NO: 4, wherein the substitution produces enhanced binding of the modified receptor binding domain to human Syt II as compared to an identical molecule lacking the substitution.
US Pat. No. 10,193,187

IONIC LIQUIDS FOR SOLVATING LITHIUM POLYSULFIDES

NOHMS Technologies, Inc.,...

1. A method of controlling the solvation of polysulfide anions in a mixture by incorporating a plurality of a functionalized single ionic liquid molecule described by the formula C+A?, whereina. A? is an anion selected from the group consisting of halides, nitrates, phosphates, imides, borates, phosphazines, acetates, and sulfonates; and
b. C+ is an organic cation selected from the group consisting of ammoniums, sulfoniums, phosphoniums, and any 5 or 6 membered heterocyclic ring having 1 to 3 heteroatoms as ring members selected from nitrogen, oxygen, and sulfur,wherein one or more of the atoms in the heterocyclic ring of the cation are substituted with one or more moieties selected from the group consisting of halides, oxygen, nitrogen, sulfur, phosphorus, alkanes, esters, ethers, ketones, carbonyls, alkoxyalkanes, alkenes, alkynes, aryls, nitriles, silanes, sulfones, thiols, phenols, hydroxyls, amines, imides, aldehydes, carboxylic acids, carbonates, and acid anhydrides; andwherein any of the carbon or hydrogen atoms in the above moieties are further substituted with halides, oxygen, nitrogen, sulfur, phosphorus, alkanes, esters, ethers, ketones, carbonyls, alkoxyalkanes, alkenes, alkynes, aryls, nitriles, silanes, sulfones, thiols, phenols, hydroxyls, amines, imides, aldehydes, carboxylic acids, carbonates, and acid anhydrides.
US Pat. No. 10,189,086

METHOD AND APPARATUS FOR MANUFACTURING POROUS THREE-DIMENSIONAL ARTICLES

ARCAM AB, Moelndal (SE)

1. A method for manufacturing a porous three-dimensional article comprising the steps of:creating a model of a non-porous three-dimensional article comprising a predetermined number of layers with a predetermined thickness;
creating a model of a porous structure, said creating step comprising the steps of:
defining a completely randomized three-dimensional space comprising a randomized arrangement of nodes, said randomized arrangement of nodes defined by the steps of:
a. identifying a predetermined number of said nodes initially arranged randomly in the three-dimensional space of predetermined size;
b. determining a maximum number of neighbor nodes to a specific node;
c. skipping a number x of closest neighbors to said specific node where x is a random integer number being ?0;
d. connecting each of said maximum neighbor nodes, with the exception of the skipped nodes, to said specific node with a strut; and
e. repeating steps a-d for each node in the three-dimensional space,
wherein said nodes are connected together in the randomized arrangement using struts, wherein said randomized arrangement is randomized in every direction of the completely randomized three-dimensional space, and wherein said randomized arrangement lacks periodicity, such that due to the lacking periodicity, a mechanical strength of a porous structure created therefrom is equal in all directions;
slicing said completely randomized three-dimensional space into a predetermined number of layers with a predetermined thickness;
applying one layer of said model of the non-porous three-dimensional article on one layer of said randomized three-dimensional space resulting in a model of a porous layer of said porous three-dimensional article; and
repeating said applying step for all layers of said model of the non-porous three-dimensional article; and
manufacturing the porous three-dimensional article by exposing fusible material to an energy source, so that a layer of fused material is corresponding to the model of the porous layer of said porous three-dimensional article,
wherein said porous three-dimensional article lacks periodicity.
US Pat. No. 10,190,111

ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

Portola Pharmaceuticals, ...

1. An isolated two-chain polypeptide comprising:1) a first chain comprising amino acid residues 1-105 of SEQ ID NO: 22, and
2) a second chain comprising amino acid residues 112-365 of SEQ ID NO: 22,
wherein the two-chain polypeptide (a) has reduced catalytic activity as compared to the corresponding wild-type factor Xa protein, (b) is capable of binding to a factor Xa inhibitor and (c) cannot assemble into a prothrombinase complex.
US Pat. No. 10,193,188

AQUEOUS ELECTROLYTE WITH ETHERS AND BATTERIES USING THE ELECTROLYTE

5. A lithium ion battery comprising:an anode capable of intercalation and de-intercalation of lithium ions;
a cathode comprising an active material selected from the group consisting of LiMn2O4, LiCoO2, LiFe(PO4), LiMn1/3Ni1/3Co1/3O2, LiNi0.5Mn1.5O4 and LiCoPO4; and
an aqueous electrolyte in contact with the anode and cathode which comprises:
water;
at least one of a linear ether and a cyclic ether; and
a lithium salt of an anion comprising a fluoroalkylsulfonyl group of formula (I):
R—SO2-  (I)
wherein R is a perfluoroalkyl group of 1-5 carbons, and
wherein relative mole ratios of ether (Y) and water (Z) to Li-salt of formula satisfy the following formulas:
Y/X is from 1/10 to 50/1; and
Z/X is from 1/10 to 5/1.
US Pat. No. 10,188,061

SOYBEAN VARIETY 01064486

Monsanto Technology LLC, ...

1. A plant of soybean variety 01064486, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124958.
US Pat. No. 10,190,112

METHOD FOR THE BIOCATALYTIC CYCLIZATION OF TERPENES AND CYCLASE MUTANTS EMPLOYABLE THEREIN

BASF SE, Ludwigshafen am...

1. An enzyme mutant with cyclase activity which is a mutant of a wild-type enzyme comprising the amino acid sequence of SEQ ID NO: 209 with a mutation at a position corresponding to position F445 of the amino acid sequence of SEQ ID NO: 209, wherein up to 10% of the amino acid residues in said enzyme mutant are altered relative to the amino acid sequence of SEQ ID NO: 209 by deletion, insertion, substitution, addition, inversion, or a combination thereof, and wherein said enzyme mutant catalyzes at least the cyclization of a citronellal isomer to at least one isopulegol isomer.
US Pat. No. 10,188,062

SOYBEAN CULTIVAR S170037

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170037, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124480.
US Pat. No. 10,190,113

METHODS AND COMPOSITIONS FOR SEGREGATING TARGET NUCLEIC ACID FROM MIXED NUCLEIC ACID SAMPLES

FLIR DETECTION, INC., St...

1. A method for enriching a target nucleic acid in a mixed sample containing the target nucleic acid and a non-target nucleic acid, comprising:(i) digesting the mixed sample with a methylation-sensitive or methylation-dependent endonuclease that cleaves the target nucleic acid and not the non-target nucleic acid;
(ii) digesting the sample with an endonuclease; wherein the endonuclease cleaves the non-target nucleic acid and not the target nucleic acid, resulting in non-target nucleic acid ends that do not bind to the cleaved target nucleic acid;
(iii) circularizing the cleaved target nucleic acid; wherein the circularized target nucleic acid is resistant to digestion with DNase or exonuclease; and
(iv) depleting the non-target nucleic acid.
US Pat. No. 10,188,063

LACTUCA SATIVA CULTIVAR FRAZIER

Proscreen Ag Technology, ...

1. A seed of lettuce cultivar designated FRAZIER, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-125178.
US Pat. No. 10,188,064

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH246236

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH246236, produced by crossing a first plant of variety CV462675 with a second plant of variety CV507905, wherein representative seeds of said varieties CV462675 and CV507905 are deposited under ATCC Accession Nos. PTA-124501 and PTA-123822, respectively.
US Pat. No. 10,190,115

METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS

Bio-Rad Laboratories, Inc...

1. A composition comprising a plurality of second partitions containing first partitions, wherein:a. said first partitions are degradable upon the application of a stimulus to said first partitions such that contents of a first partition is mixed with contents of a second partition; and
b. said first partitions are contained within the second partitions;
c. said first partitions contain an oligonucleotide barcode; and
d. the first partitions have on average a first average volume and the second partitions have on average a second average volume, wherein the second average volume is at least twice as large as the first average volume.
US Pat. No. 10,189,859

DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE

Nektar Therapeutics, San...

1. A 6-(2,3-dichlorophenyl)-1,2,4-triazine-5 amine compound having an N-bonded substituent at the 3-position of the triazine ring and an amino (—NH2) group at the 5-position of the triazine ring, wherein the N-bonded substituent is an amino nitrogen covalently attached to the 3-carbon of the triazine ring, wherein the amino nitrogen forms part of a substituted or unsubstituted nitrogen-containing heterocycle selected from the group consisting of a substituted or unsubstituted piperazine, a substituted or an unsubstituted pyrrolidine, a substituted or an unsubstituted azetidine, and a substituted or an unsubstituted diazetidine, where any of the foregoing nitrogen-containing heterocycles may form part of a bi- or a tricylic ring structure,wherein a substituted nitrogen-containing heterocycle comprises one or more substituents, where the substituent is a linear or a branched alkyl chain, and/or comprises an oligomeric ethylene oxide chain, which may be further substituted with one or more functional groups selected from C1-C6 alkyl ether, amino, hydroxyl, carboxyl, aldehyde, alkylsulfone, tetrazole, oxetane, C2-C6 carbonate ester, alkyl ester, alkylsulfoxide, halo, amido, sulfonamide, cycloalkyl, heterocyclyl, —CF3, —CF2H, and —CFH2, and wherein the dichlorophenyl ring may possess an additional substituent at any one of positions 4, 5 or 6,
or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,188,066

MAIZE HYBRID X03M280

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X03M280, representative seed produced by crossing a first plant of variety PH42YG with a second plant of variety PH2DPY, wherein representative seed of the varieties PH42YG and PH2DPY have been deposited under ATCC Accession Numbers PTA-124780 and PTA-124001, respectively.
US Pat. No. 10,190,117

DOUBLE-STRANDED ANTISENSE NUCLEIC ACID WITH EXON-SKIPPING EFFECT

National University Corpo...

1. A pharmaceutical composition for modulating exon skipping of a coding or non-coding RNA in a mammalian cell comprising:a double-stranded nucleic acid complex comprising:
a first nucleic acid strand annealed to a second nucleic acid strand, wherein:
the first nucleic acid strand comprises (i) 8 to 100 nucleotides independently selected from natural nucleotides, modified nucleotides, and nucleotide analogs, (ii) at least one region consisting of 2 or 3 consecutive natural DNA nucleotides, (iii) no regions that have greater than 3 consecutive natural DNA nucleotides, and (iv) a bridged nucleotide/DNA mixmer oligonucleotide; and wherein the first nucleic acid strand is a splice-switching oligonucleotide (SSO) and is capable of hybridizing to the coding or non-coding RNA inside of the mammalian cell; and
the second nucleic acid strand comprises nucleotides independently selected from natural RNA nucleotides, modified RNA nucleotides, and nucleotide analogs, and at least one region comprising consecutive natural RNA nucleotides,wherein the at least one region consisting of 2 or 3 consecutive natural DNA nucleotides of the first nucleic acid strand forms a heteroduplex with the at least one region comprising consecutive natural RNA nucleotides of the second nucleic acid strand.
US Pat. No. 10,188,067

MAIZE HYBRID X08M611

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X08M611, representative seed produced by crossing a first plant of variety PH41R5 with a second plant of variety PH4257, wherein representative seed of the varieties PH41R5 and PH4257 have been deposited under ATCC Accession Numbers PTA-124793 and PTA-124803, respectively.
US Pat. No. 10,190,118

METHODS AND COMPOSITIONS FOR TREATING INSECTS

ALNYLAM PHARMACEUTICALS, ...

1. A method for treating disease in an insect, the method comprising administering to the insect a composition comprising a double stranded RNA (dsRNA) molecule or a vector encoding a dsRNA molecule, and a delivery agent, wherein the dsRNA molecule is 19-24 nucleotides long, comprises a sense strand and an antisense strand, and modulates gene expression of an insect, wherein the double-stranded region of the dsRNA is about 19 nucleotides in length, andwherein the dsRNA further comprises (i) at least one mismatch, (ii) a 5?-terminal dinucleotide overhang, or a 3?-terminal dinucleotide overhang, or both a 5?- and 3?-dinucleotide overhang, and (iii) at least one asymmetrical modification, and
wherein the dsRNA molecule comprises at least one nucleotide modification to increase stabilization of the dsRNA, the modification selected from the group consisting of:
(i) a 5?-phosphorothioate or 5?-phosphorodithioate modifications within the double stranded region,
(ii) a phosphorothioate modification within the nucleotides at the terminal overhang region,
(iii) a cationic modification of nucleotides 1 and 2 on the 5? terminus, wherein the cationic modification is at the C5 position of pyrimidines and C2, C6 and C8, exocyclic N2 or exocyclic N6 of purines,
(iv) at least one 2?-fluoro modified nucleotide comprising a nucleobase modification
(v) at least one 2?-O-methyl/2?-fluoro modified nucleotide comprising a nucleobase modification,
(vi) a 5?-PuPu-3? dinucleotide at the 3? terminal of at least one of the strands in the dsRNA molecule wherein both nucleotides comprise a modified methoxyethyl (MOE) at 2?-position, and
(vii) a 5?-PuPu-3? dinucleotide at the 5? terminal of at least one of the strands in the dsRNA molecule wherein both nucleotides comprise a modified MOE at 2?-position; and
wherein modulation of the gene treats the disease.
US Pat. No. 10,191,398

ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE

Ricoh Company, Ltd., Tok...

8. An electrophotographic photoconductor, comprising:a conductive support having a volume resistivity of 1×1010?·cm or less;
an undercoat layer; and
a photoconductive layer,
wherein the undercoat layer and the photoconductive layer being disposed on the conductive support in an order mentioned,
wherein the undercoat layer comprises:
zinc oxide particles;
a urethane bond-containing resin; and
methylethyl ketone oxime,
wherein an amount of the methylethyl ketone oxime included in the undercoat layer is from 2,888 ppm to 5,000 ppm, and
wherein the undercoat layer satisfies a formula below:
10 where M is a ratio (ppm) of the methylethyl ketone oxime comprised in the undercoat layer, and L is an average thickness (?m) of the undercoat layer.
US Pat. No. 10,188,068

MAIZE HYBRID X08M612

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X08M612, representative seed produced by crossing a first plant of variety PH41V8 with a second plant of variety PH2SRH, wherein representative seed of the varieties PH41V8 and PH2SRH have been deposited under ATCC Accession Numbers PTA-124794 and PTA-124300, respectively.
US Pat. No. 10,189,606

DRINKING OR EATING VESSEL

AT Promotions LTD, Kings...

1. A drinking or eating vessel comprising an inner surface that defines a volume for receiving liquid or solid food and an outer surface that supports a polymeric coating and a decorative layer,wherein the polymeric coating comprises a polymer formed by curing a coating mixture on the outer surface of the drinking or eating vessel, said coating mixture comprising a matting agent,
the polymeric coating has an inner surface in contact with the drinking or eating vessel and an outer surface in contact with the decorative layer, and
the decorative layer comprises a dry toner image applied to the outer surface of the polymeric coating.
US Pat. No. 10,190,119

MITOCHONDRIAL PHOSPHATE CARRIER TARGETS FOR TREATING SOFT-TISSUE CALCIFICATION

1. A method of treating soft-tissue calcification in a coronary artery or heart valve in a subject, the method comprising administering a therapeutically-effective amount of an inhibitor of solute carrier family 25 member 24 (SLC25A24) to the subject, wherein the SLC25A24 inhibitor comprises at least one small interfering RNA (siRNA) comprising a targeting sequence selected from the group consisting of: CAGAUGAAUUCACGGAAGA (SEQ ID NO: 1), GCAUAUGAACAGUACAAGA (SEQ ID NO: 2), GGAAAUGGUACAAACGUCA (SEQ ID NO: 3), and GGUGCUGUCUCUCGAACAA (SEQ ID NO: 4) wherein the SLC25A24 inhibitor decreases the expression level of SCL25A24.
US Pat. No. 10,190,631

SLIDING ENGINE COMPONENT

Mahle International GmbH,...

8. A sliding engine component according to claim 1, further comprising a plastic polymer-based layer that does not contain a thermochromic material, which is disposed between the metallic substrate and the sliding surface.
US Pat. No. 10,188,069

SOYBEAN CULTIVAR CL1460745

Syngenta Participations A...

1. A plant, a plant part, or a seed of soybean variety CL1460745, wherein a representative sample of seed of said soybean variety CL1460745 has been deposited under ATCC Accession Number PTA-123857.
US Pat. No. 10,188,070

SOYBEAN CULTIVAR CL1460155

Syngenta Participations A...

1. A plant, a plant part, or a seed of soybean variety CL1460155, wherein a representative sample of seed of said soybean variety CL1460155 has been deposited under ATCC Accession Number PTA-123841.
US Pat. No. 10,190,122

INHIBITORY OLIGONUCLEOTIDE AND USE THEREOF

SBI Biotech Co., Ltd., T...


US Pat. No. 10,188,072

SOYBEAN VARIETY 01064694

Monsanto Technology LLc, ...

1. A plant of soybean variety 01064694, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124971.
US Pat. No. 10,189,610

STERILIZABLE PVC-FREE CLOSURES

ACTEGA DS GMBH, Bremen (...

1. A vessel cap made of metal or plastic for a vessel for receiving foods or beverages, comprising a seal insert made of a seal material which comprises at least three different polymers mixed with further substances,wherein the seal material comprises no polyvinyl chloride (PVC),
wherein the seal material is substantially free from components that are liquid at application temperature,
wherein the seal material has a Shore A hardness between 40 and 95,
wherein the seal material comprises at least three different polymers, wherein the first polymer is a propylene polymer and/or propylene copolymer, the second polymer is a thermoplastic elastomer, and the third polymer is a polyolefin elastomer,
wherein the seal material is composed such that the seal insert withstands a sterilization at temperatures of above 100° C. and up to 132° C.,
and wherein the seal material, in a dynamic mechanical thermal analysis (DMTA), demonstrates a heating curve for the phase angle tan (delta) the inflection point of which lies above the required sterilization temperature.
US Pat. No. 10,190,123

ENGINEERING OF MULTI-CARBON SUBSTRATE UTILIZATION PATHWAYS IN METHANOTROPHIC BACTERIA

CALYSTA, INC., Menlo Par...

1. A recombinant methanotrophic bacterium, comprising at least one exogenous nucleic acid encoding a glucose utilization pathway component,wherein glucose is not utilized as a primary carbon source by an unmodified parent methanotrophic bacterium;
wherein the encoded glucose utilization pathway component comprises a glucose transporter selected from the group consisting of phosphoenolpyruvate:glucose phosphotransferase system, a glucose-ion symporter, an ABC transporter, a glucose/galactose transporter (GluP), or a galactose permease (GalP) and is expressed in a sufficient amount to permit growth of the recombinant methanotrophic bacterium on glucose as a primary carbon source; and
wherein the methanotrophic bacterium is selected from Methylococcus capsulatus, Methylornonas sp. 16A, Methylosinus trichosporium, Methylosinus sporium, Methylacystis parvus, Methylomonas methanica, Methylomonas albus, Methylobacter capsulatus, Methylomonas flagellata, Methylacidiphilum infernorum, Methylomicrobium alcaliphilum, Methylocella silvestris, Methylocella palustris, Methylocella tundrae, Methylocystis daltona, Methylocystis bryophila, or Methylocapsa aurea.
US Pat. No. 10,188,074

SOYBEAN VARIETY 5PKCF87

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PKCF87, representative seed of the variety having been deposited under ATCC Accession Number PTA-125527.
US Pat. No. 10,190,125

HAPLOID INDUCTION COMPOSITIONS AND METHODS FOR USE THEREFOR

Syngenta Participations A...

1. A method of creating a new haploid inducer maize plant with a silenced patatin-like phospholipase 2A, comprising transcribing a polynucleotide sequence that silences the patatin-like phospholipase 2A in maize, wherein said polynucleotide sequence comprises a first sequence selected from the group consisting of:a) a polynucleotide sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 33 or the complement thereof;
b) a functional fragment comprising at least 22 contiguous bases of SEQ ID NO: 33 or the complement thereof; and
c) a polynucleotide sequence having at least 95% sequence identity as determined using the BLASTN alignment tool to the nucleic acid sequence set forth in SEQ ID NO: 33 or the complement thereof,and a second sequence that is the complement of the first sequence, wherein the polynucleotide sequence expresses a double-stranded ribonucleotide sequence which silences the patatin-like phospholipase 2A when contacted with a maize plant and thus creates a new haploid inducer maize plant.
US Pat. No. 10,188,075

SOYBEAN VARIETY 5PKDS07

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PKDS07, representative seed of the variety having been deposited under ATCC Accession Number PTA-125528.
US Pat. No. 10,190,126

TRANSGENIC PLANTS WITH MODIFIED SUGAR CONTENT AND METHODS OF GENERATING SAME

A.B. Seeds Ltd., (IL)

1. A method of increasing the sucrose level or increasing the sucrose to glucose ratio in a tomato plant comprising expressing in said tomato planta DNA encoding a miR397-, miR528-, or miR1110-resistant target gene, wherein said miR397-, miR528-, or miR1110-resistant target gene comprises an introduced silent mutation in a nucleotide sequence that is otherwise substantially identical to the nucleotide sequence of an endogenous gene that is natively regulated by miR397, miR528, or miR1110, and wherein said silent mutation prevents binding by a mature miR397, miR528, or miR1110 to a transcript of said miR397-, miR528-, or miR1110-resistant target gene,
wherein the sucrose level or the sucrose-to-glucose ratio is increased in said tomato plant.
US Pat. No. 10,188,589

DEPOSITION OF HYDROPHOBIC ACTIVES IN THE PRESENCE OF SURFACTANTS

Dow Global Technologies L...

1. A personal care composition, comprising:an anionic surfactant; and
a polyurea shell encapsulating a hydrophobic personal care active selected from the group consisting of a fragrance, a vitamin, an extract, or a therapeutic active, wherein the polyurea shell has at least one covalently attached cationic polymer, selected from the group consisting of quaternary amines and cationic biopolymers, wherein the polyurea shell has at least one covalently attached quaternary amine that is the reaction product of (2-Aminoethyl) trimethylammonium chloride and polyisocyanate.
US Pat. No. 10,190,127

METHODS AND MEANS FOR OBTAINING MODIFIED PHENOTYPES

COMMONWEALTH SCIENTIFIC A...

1. A process for producing an unpolyadenylated RNA, the process comprising a step of culturing a cell comprising a chimeric DNA under conditions suitable for expressing the chimeric DNA, wherein the chimeric DNA comprises a promoter operably linked to a target specific DNA region which encodes an unpolyadenylated hairpin RNA,wherein the target specific DNA region comprises a target specific sense nucleotide sequence and a target specific antisense nucleotide sequence,
wherein the target specific antisense nucleotide sequence comprises 20 consecutive nucleotides in a sequence identical to the sequence of a complement of a part of an RNA molecule transcribed or produced from a nucleic acid of interest,
wherein the target specific sense nucleotide sequence comprises consecutive nucleotides in a sequence identical to the sequence of the part of the RNA molecule transcribed or produced from the nucleic acid of interest,
wherein the target specific sense nucleotide sequence and the target specific antisense nucleotide sequence are separated and linked by a spacer sequence, such that the unpolyadenylated hairpin RNA resulting from transcription of the target specific DNA region comprises the spacer sequence located between sense and antisense nucleotide sequences in the unpolyadenylated hairpin RNA, and
wherein the sense and antisense nucleotide sequences are complementary to each other so as to form the unpolyadenylated hairpin RNA.
US Pat. No. 10,189,871

TRANSITION METAL COMPLEXES FOR ENANTIOSELECTIVE CATALYSIS OF CARBON-CARBON, CARBON-HETEROATOM, AND CARBON-HYDROGEN BOND FORMING REACTIONS

1. A compound, comprising a transition metal complex having the formula ?-[M ((x,y)-L1)3?b?c((w,v)-L2)b((t,u)-L3)c]p+An?m,Z?p?m, wherein ? is ? or ?, wherein M is a transition metal, wherein p is an integer corresponding to the oxidation state of M, wherein each of x, y, w, v, t, and u independently comprises one of R and S, wherein each of L1 and L2 independently is a ligand comprising ethylene diamine, wherein L3 is EN(CH2)nNR1R2, wherein EN represents ethylene diamine, wherein n is from 2 to 4, and wherein R1 and R2 are independently H or alkyl groups, wherein c is from 1 to 3, wherein b is from 0 to 2, wherein An? comprises a lipophilic anion, wherein m is from 1 to 3, and wherein Z? comprises a second anion.
US Pat. No. 10,190,128

KITS COMPRISING PLUS-SENSE SINGLE STRANDED RNA VIRAL VECTORS AND METHODS FOR PRODUCING POLYPEPTIDES USING THE KITS

1. A kit comprisinga) a first plus-sense single stranded ribonucleic acid (RNA) viral vector, and
b) a second plus-sense single stranded RNA viral vector,
wherein
(i) the first plus-sense single-stranded viral vector and the second plus-sense single-stranded viral vector are derived from different plant viruses, and
(ii) the coat protein open reading frame (ORF) of the virus from which the first vector is derived is completely deleted in the first plus-sense single stranded RNA viral vector, and
(iii) the coat protein ORF of the virus from which the second vector is derived is completely deleted in the second plus-sense single stranded RNA viral vector, and
(iv) the first plus-sense single stranded RNA viral vector comprises a functional coat protein ORF of the virus from which the second plus-sense single-stranded viral vector is derived, and
(v) the second plus-sense single stranded RNA viral vector comprises a functional coat protein ORF of the virus from which the first plus- sense single-stranded viral vector is derived, and
(vi) the first plus-sense single-stranded viral vector and the second plus-sense single-stranded viral vector comprise an RNA replicon which is able to replicate in plant cells,
and wherein
the virus from which the first plus-sense single-stranded viral vector is derived is a Potexvirus, and
the virus from which the second plus-sense single-stranded viral vector is derived is a Tobamovirus.
US Pat. No. 10,188,591

METHOD OF ENHANCING HAIR GROWTH

ALLERGAN, INC., Irvine, ...

1. A method of growing eyebrow hair, comprising applying on at least one eyebrow an effective amount of a topical composition containing bimatoprost or a pharmaceutically-acceptable salt thereof.
US Pat. No. 10,190,129

INCREASING LEVELS OF NICOTINIC ALKALOIDS IN PLANTS

22nd Century Limited, LLC...

1. A method for increasing nicotine and yield in a Nicotiana plant, comprising:(a) crossing an increased nicotine Nicotiana plant that expresses heterologous NBB1 having the amino acid sequence set forth in SEQ ID NO: 2 and A622 having the amino acid sequence set forth in SEQ ID NO: 4 with a high yielding Nicotiana plant; and
(b) selecting progeny plant with increased nicotine and high yield, wherein the plant has an increased nicotine content and yield relative to a non-transformed control plant.
US Pat. No. 10,190,130

POLYSACCHARIDE SYNTHASES

The University of Melbour...

1. A method for decreasing the level of (1,3;1,4)-?-D-glucan produced by a plant or fungal cell, the method comprising decreasing the level and/or activity of a CslF-encoded (1,3;1,4)-?-D-glucan synthase in the cell, wherein the level and/or activity of the CslF-encoded (1,3;1,4)-?-D-glucan synthase is decreased by decreasing the expression of a CslF nucleic acid in the cell, and wherein decreasing the expression of a CslF nucleic acid in the cell results in a decrease of the level of (1,3;1,4)-?-D-glucan produced by the cell compared to a wild-type cell of the same taxon, and wherein the CslF nucleic acid comprises:(i) a nucleotide sequence set forth in SEQ ID NO: 1;
(ii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 2; or
(iii) a nucleotide sequence encoding an amino acid sequence which is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 2.
US Pat. No. 10,188,593

POLYSACCHARIDE DELIVERY PARTICLE

Spray-Tek, Inc., Middles...

1. A controlled release particle comprising 10-70 wt. % of a hydrophobic active ingredient, 21-72 wt. % of a polysaccharide, 3.80-12 wt. % of a crosslinking agent, 1.00-6 wt. % of a catalyst, 0.10-5 wt. % of a silica flow aid, and optionally 0.10 -5 wt. % of a desiccant, wherein the controlled release particle is anhydrous and the hydrophobic active ingredient is dispersed in a crosslinked polysaccharide matrix effective to retain the hydrophobic active ingredient upon exposure to water and effective to release the hydrophobic active ingredient in response to at least one of friction and enzymes.
US Pat. No. 10,189,874

DNA GRIDIRON COMPOSITIONS AND METHODS

Arizona Board of Regents ...

1. A composition, comprising:a plurality of immobile Holliday junction analogs wherein each junction comprises a 60° torsion angle linked together in a square frame having at least two layers in which the helices on opposite sides lie in the same plane, and wherein said plurality of immobile Holliday junction analogs are linked together with a central strand of single-stranded DNA within said square frame.
US Pat. No. 10,190,131

METHOD FOR PRODUCING POLYUNSATURATED FATTY ACIDS

BASF Plant Science GmbH, ...

1. A process for producing a transgenic plant producing eicosapentaenoic acid, docosapentaenoic acid and/or docosahexaenoic acid comprising introducing into a plant:a) a nucleic acid sequence encoding a polypeptide having ?6-desaturase activity, wherein said polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO: 2;
b) a nucleic acid sequence encoding a polypeptide having ?6-elongase activity, wherein said polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO: 172;
c) a nucleic acid sequence encoding a polypeptide having ?5-desaturase activity, wherein said polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO: 52;
d) a nucleic acid sequence encoding a polypeptide having ?5-elongase activity, wherein said nucleic acid sequence is at least 90% identical to SEQ ID NO: 64; and
e) optionally a nucleic acid sequence encoding a polypeptide having ?4-desaturase activity, wherein said polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO: 78;
wherein the nucleic acid sequence encoding the polypeptide having ?5-elongase activity is modified to adapt to the codon usage in one or more plant species.
US Pat. No. 10,189,875

ANTI-CANCER PEPTIDE AND USE THEREOF

ENSOL BIOSCIENCES INC., ...

1. A peptide consisting of the amino acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,190,132

RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ

MEDICAGO INC., Quebec (C...

1. A method of producing an influenza virus like particle (VLP) in a plant comprising:a) introducing a nucleic acid comprising a nucleotide sequence encoding an influenza hemagglutinin (HA) into a plant, or portion of a plant, the HA being operatively linked to a regulatory element that is operative in a plant and wherein the regulatory element comprises a Cowpea Mosaic Virus (CPMV) regulatory region, and
b) incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acid, thereby producing the VLP.
US Pat. No. 10,188,595

MULTI-PURPOSE COSMETIC COMPOSITIONS

Mary Kay Inc., Addison, ...

1. A method for treating the skin of a subject in need thereof comprising topically applying to the skin of said subject a cosmetic composition that includes effective amounts of a Silybum marianum extract and a Momordica grosvenori fruit extract, wherein the Silybum marianum extract is a hydroalcoholic extract and the Momordica grosvenori fruit extract is a hydroglycolic extract.
US Pat. No. 10,189,876

CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES

Aadigen, LLC, Pacific Pa...

1. A cell-penetrating peptide characterized in that it comprises an amino acid sequence consisting of X1WX2RLX3X4X5X6X7X8 (SEQ ID No: 5), wherein X1 is beta-A or S; X2, X6, and X7 are, independently from each other, W or F; X5 is S or R, and X8 is R or none, and wherein X3 is R if X5 is S, X3 is S if X5 is R, X4 is L or none if X8 is R, and X4 is L if X8 is none.
US Pat. No. 10,190,133

COMPOSITIONS AND METHODS FOR IMPROVING ABIOTIC STRESS TOLERANCE

China Agricultural Univer...

1. A recombinant nucleic acid, comprising:(a) the nucleotide sequence SEQ ID NO:1; or
(b) a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence SEQ ID NO:28,
wherein each of the nucleotide sequences of (a) and (b) is operably linked to a heterologous promoter.
US Pat. No. 10,188,596

OMEGA-7 FATTY ACID COMPOSITION, METHODS OF CULTIVATION OF TRIBONEMA FOR PRODUCTION OF COMPOSITION AND APPLICATION OF COMPOSITION

QINGDAO INSTITUTE OF BIOE...

1. A method of cultivation of Tribonema sp., comprising the steps to carry out heterotrophy and/or mixotrophy of Tribonema sp.
US Pat. No. 10,190,134

COMPOSITIONS AND METHODS FOR INSECTICIDAL CONTROL OF STINKBUGS

E I DU PONT DE NEMOURS AN...

1. An expression cassette, comprising a heterologous promoter operably linked to a polynucleotide encoding a double stranded RNA, wherein the double stranded RNA comprises the sense and antisense sequence of a nucleotide sequence selected from the group consisting of:(a) a nucleotide sequence comprising any one of SEQ ID NOS: 9, or 30-34;
(b) a nucleotide sequence comprising at least 95% sequence identity to any one of SEQ ID NOS: 9, or 30-34; and
(c) a nucleotide sequence comprising at least 23 consecutive nucleotides of any one of SEQ ID NOS: 9, or 30-34;
wherein said double stranded RNA has insecticidal activity against a Pentatomidae plant pest.
US Pat. No. 10,189,878

EBOLAVIRUS PRE-HAIRPIN INTERMEDIATE MIMICS AND METHODS OF USE

University of Utah Resear...

1. An Ebolavirus N-trimer mimic comprising a homotrimer of peptide monomers, wherein each peptide monomer comprises an an amino acid sequence of SEQ ID NO:23 or SEQ ID NO:21.
US Pat. No. 10,189,879

DNA-BINDING PROTEIN USING PPR MOTIF, AND USE THEREOF

HIROSHIMA UNIVERSITY, Hi...

1. A pentatricopeptide repeat (PPR) fusion protein comprising:9 PPR motifs belonging to the p63 protein consisting of the amino acid sequence of SEQ ID NO: 1,
11 PPR motifs belonging to the GUN1 protein consisting of the amino acid sequence of SEQ ID NO: 2,
15 PPR motifs belonging to the pTac2 protein consisting of the amino acid sequence of SEC) ID NO: 3,
10 PPR motifs belonging to the DG1 protein consisting of the amino acid sequence of SEQ ID NO: 4, or
11 PPR motifs belonging to the GRP23 protein consisting of the amino acid sequence of SEQ ID NO: 5; and
a nuclear transfer signal inserted at an N-terminus of the PPR protein, wherein the nuclear transfer signal is encoded by a polynucleotide consisting of positions 165-185 of any one of SEQ ID NOs: 7-9.
US Pat. No. 10,190,136

MOUSE MODEL OF ALPHA-ONE ANTITRYPSIN (AAT) DEFICIENCY

University of Massachuset...

1. A transgenic mouse whose genome comprises inactivating mutations in exon 2 of each of Serpina1a, Serpina1b, Serpina1c, Serpina1d, and Serpina1e genes, and which expresses no hepatic or circulatory Alpha-One Antitrypsin (AAT) protein.
US Pat. No. 10,190,137

CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS

Editas Medicine, Inc., C...

1. A composition comprising:(a) a nucleic acid encoding a Cas9 molecule, wherein the Cas9 molecule is an S. aureus or S. pyogenes Cas9 molecule, and a nucleic acid encoding a first guide RNA (gRNA) molecule; and
(b) a governing gRNA molecule that comprises a nucleotide sequence targeting domain that targets said nucleic acid encoding said Cas9 molecule and/or said nucleic acid encoding said first gRNA molecule, wherein the nucleotide sequence targeting domain is 15 to 30 nucleotides in length, andwherein(i) the first gRNA molecule comprises a sequence that targets a target nucleic acid,
(ii) the governing gRNA molecule comprises a sequence that targets the nucleic acid encoding the Cas9 molecule and/or the nucleic acid encoding the first gRNA, and
(iii) the nucleotide sequence targeting domain of the governing gRNA molecule is selected from the group consisting of:
a nucleotide sequence targeting domain that provides a Cas9 molecule-mediated cleavage event in the Cas9 molecule-amino acid coding sequence of the nucleic acid sequence or in the gRNA molecule-coding sequence of the nucleic acid encoding said first gRNA molecule;
a nucleotide sequence targeting domain that provides a Cas9 molecule-mediated cleavage event in a non-coding sequence of the nucleic acid encoding the Cas9 molecule;
a nucleotide sequence targeting domain that provides a Cas9 molecule-mediated cleavage event in an untranslated sequence of the nucleic acid encoding the Cas9 molecule;
a nucleotide sequence targeting domain that provides a Cas9 molecule-mediated cleavage event 5? of the Cas9 molecule-coding region of the nucleic acid encoding the Cas9 molecule;
a nucleotide sequence targeting domain that provides a Cas9 molecule-mediated cleavage event 3? of the Cas9 molecule-coding region of the nucleic acid encoding the Cas9 molecule;
a nucleotide sequence targeting domain that provides a Cas9 molecule-mediated cleavage event in the promoter region of the nucleic acid encoding the Cas9 molecule, wherein the promoter region is functionally linked to the Cas9 molecule amino acid coding region; and
a nucleotide sequence targeting domain that provides a Cas9 molecule-mediated cleavage event in an intronic sequence of the nucleic acid encoding the Cas9 molecule.
US Pat. No. 10,190,649

FRICTION MATERIAL

AKEBONO BRAKE INDUSTRY CO...

1. A friction material comprising:a fiber base material;
a friction modifier; and
a binder,
wherein a content of copper is 0.5% by mass or less in terms of copper element,
wherein a content of the binder is 10% by mass or more,
wherein the friction material contains calcium hydroxide and zinc,
wherein the friction material has pH of 113 or more,
wherein a content of the zinc is from 1% by mass to 5% by mass,
wherein the zinc comprises a powder having an average particle diameter in a range of 1 ?m to 10 ?m,
wherein the calcium hydroxide comprises powder having an average particle diameter in a range of 5 ?m to 50 ?m,
wherein the fiber base material comprises a bio-soluble inorganic fiber, and
wherein the binder consists of at least one selected from the group consisting of an acrylic rubber-modified phenol resin, a silicone rubber-modified phenol resin, an NBR rubber-modified phenol resin, a cashew-modified phenol resin, an epoxy-modified phenol resin and an alkylbenzene-modified phenol resin.
US Pat. No. 10,189,881

MPS PEPTIDES AND USE THEREOF

The Regents of the Univer...

1. A method for one or more of: reducing, delaying, inhibiting or suppressing solid tumor cell growth or metastasis; promoting apoptosis; inhibiting cancer stem cell growth; inhibiting the PIP3 level in a tumor cell; or suppressing tumor cell mobility, the method comprising contacting the cell or tissue to be treated in vivo with an effective amount of an isolated polypeptide comprising no more than 51 amino acids, wherein the amino acid sequence comprises:XXXRYSYXXSYX (SEQ ID NO: 1) and optionally, wherein one or more serines has been substituted with a neutral or positively charged amino acid, wherein each X is a lysine and wherein each Y is a phenylalanine; or
XXXXXRYSYXXSYXLSGYSYXXNXX (SEQ ID NO: 5), and optionally a polypeptide comprising any contiguous 12 amino acid fragment thereof, and/or optionally, wherein one or more serines has been substituted with a neutral or positively charged amino acid and wherein each X is a lysine and wherein each Y is a phenylalanine.
US Pat. No. 10,188,601

CONTINUOUS LONG-TERM CONTROLLED RELEASE OF TELOMERASE INHIBITORS

Brenda Laster, Meitar (I...

1. A solid implant device suitable for the long-term, controlled release of a telomerase-inhibiting agent comprising Pd-meso-tetra(N-methyl-4-pyridyl)-porphyrin into tumor tissue, wherein said device comprises a homogeneous solid mixture of the Pd-meso-tetra(N-methyl-4-pyridyl)-porphyrin and poly-(lactic-co-glycolic) acid copolymer formulated for a long term controlled release of greater than 19 days of said Pd-meso-tetra(N-methyl-4-pyridyl)-porphyrin, wherein said implant device is in the form of a solid body that is implantable directly into tumor tissue, and wherein the solid mixture has a degree of homogeneity that can be obtained by solidifying a homogeneous solution of the Pd-meso-tetra(N-methyl-4-pyridyl)-porphyrin and the poly-(lactic-co-glycolic) acid copolymer.
US Pat. No. 10,189,882

METHODS FOR TREATING MYELODYSPLASTIC SYNDROMES AND SIDEROBLASTIC ANEMIAS

ACCELERON PHARMA INC., C...

1. A method for treating sideroblastic anemia in a human patient, comprising administering to a patient in need thereof a polypeptide comprising the amino acid sequence of SEQ ID NO: 44, and wherein the patient is on a dosing schedule that comprises administering from 0.75-1.75 mg/kg of the polypeptide to the patient, wherein the patient has bone marrow cells that test positive for one or more mutations in one or more of SF3B1, DNMT3A or TET2.
US Pat. No. 10,190,139

METHOD FOR LACTIC ACID PRODUCTION USING MONASCUS STRAINS MODIFIED FOR LACTIC ACID PRODUCTION

1. A method of producing a composition comprising lactic acid, the method comprising:(i) providing a Monascus micro-organism that is tolerant to organic acid at a concentration of at least 50 g/L and a pH of less than 5.0 and has been genetically modified for increased production of a lactic acid by the introduction of an exogenous lactate dehydrogenase (LDH) gene; and
(ii) culturing the micro-organism in a medium having a pH less than 1.5 units above the pKa value of lactic acid in the presence of hexose, pentose, or a combination thereof, as the sole carbon source.
US Pat. No. 10,189,883

THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES

BRISTOL-MYERS SQUIBB COMP...

1. A method of decreasing or inhibiting fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having at least 96% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.
US Pat. No. 10,190,140

INCREASED PRODUCTION OF TERPENES AND TERPENOIDS

EVOLVA SA, Reinach (CH)

1. A method for producing a terpene or a terpenoid in a recombinant host cell, comprising culturing the recombinant host cell under conditions wherein the terpene or terpenoid is produced in the recombinant host cell, wherein the recombinant host cell is genetically engineered to produce reduced expression of an endogenous farnesyl diphosphate (FPP) synthase, an endogenous geranyl diphosphate (GPP) synthase or an endogenous enzyme having both FPP synthase and GPP synthase activity compared to a non-engineered host cell;wherein reduced expression is produced in the recombinant host cell by:
(a) introducing into the recombinant host cell a heterologous genetic construct encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to an exogenous weak promoter, wherein the weak promoter is KEX2, PGK-1, GPD1, ADH1, ADH2, PYK1, TPi1, PDC1, TEF1, TEF2, FBA1, GAL1-10, CUP1, MET2, MET14, MET25, CYC1, GAL1-S, GAL1-L, TEF1, CAG, CMV, human UbiC, RSV, EF-1alpha, SV40, Mt1, Tet-On, Tet-Off, Mo-MLV-LTR, Mx1, progesterone, RU486 or Rapamycin-inducible promoter;
(b) introducing into the recombinant host cell a heterologous genetic construct encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to a messenger RNA destabilizing motif, comprising a M1 motif of SEQ ID NO:28 and/or a M24 motif of SEQ ID NO:29; or
(c) introducing into the recombinant host cell a recombinant genetic construct, the construct comprising a gene encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to an endogenous promoter, wherein between the endogenous promoter and the gene encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity is a heterologous insert sequence having the formula:
-X1-X2-X3-X4-X5-;
wherein X2 comprises at least 4 consecutive nucleotides being complementary to, and forming a hairpin secondary structure element with at least 4 consecutive nucleotides of X4;
wherein X3 either comprises zero nucleotides or one or more unpaired nucleotides forming a hairpin loop between X2 and X4;
wherein X4 comprises at least 4 consecutive nucleotides being complementary to, and forming a hairpin secondary structure element with at least 4 consecutive nucleotides of X2; and
wherein X1 and X5 comprise zero, one or more nucleotides
wherein the recombinant host cell further comprises one or more recombinant expression constructs encoding heterologous enzymes for producing said terpene or terpenoid; and
wherein the recombinant host cell further comprises a recombinant expression construct encoding a truncated version of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGR), comprising the catalytically active carboxyl terminal portion thereof, comprising a region from amino acid 619 to amino acid 1025 of SEQ ID NO:8 and having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:8.
US Pat. No. 10,188,603

TOPICAL SYSTEMS AND METHODS FOR TREATING SEXUAL DYSFUNCTION

Transdermal Biotechnology...

1. A method, comprising:providing a sealed container containing a composition comprising molecular nitric oxide, a peptide, and phosphatidylcholine, wherein the sealed container contains less than about 20 mol % oxygen;
unsealing the sealed container to allow access to the composition; and
administering the composition to a subject having or at risk of sexual dysfunction.
US Pat. No. 10,189,884

THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF

The Trustees of the Unive...

1. A peptide comprising the thioamide-modified amino acid sequence of SEQ ID NO:2, or a salt or solvate thereof,wherein residue 1 of SEQ ID NO:2 is the N-terminus residue of the peptide.
US Pat. No. 10,188,604

MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME

1. A method of treating or preventing a disease, disorder, or condition of the eye of a subject, comprising;a. providing a subject in need of treatment or prevention of said disease, disorder, or condition of the eye of said subject; and
b. providing at least one drug delivery contact lens, comprising:
i. a contact lens comprising a first surface and a second surface; and
ii. said contact lens further comprising at least one coating provided on at least a portion of said first surface, said second surface, or a combination thereof as opposed to within said contact lens;
a) said coating comprising at least one three dimensional structure;
b) said three dimensional structure comprising:
i) one or more drug reservoir layers; wherein said one or more drug reservoir layers comprise one or more drugs; and
ii) one or more barrier layers; wherein said one or more barrier layers modulafe the release of said one or more drugs from said drug delivery contact lens;
c) wherein said one or more drug reservoir layers, said one or more barrier layers, or a combination thereof, are oriented vertically, horizontally, or a combination thereof, relative to each other;
c. operably engaging said drug delivery contact lens with the eye of said subject;
wherein said one or more drugs are released from said drug delivery contact lens in an effective amount to treat or prevent a disease, disorder, or condition of the eye of said subject; and
d. wherein said subject is treated for or prevented from having or developing said disease, disorder, or condition of the eye of said subject; and
wherein said disease, disorder, or condition of the eye of said subject that is treated or prevented is an inflammation, an allergy, an infection, glaucoma, macular degeneration, a parasite, diabetes, dry eye, eye discomfort, or a combination thereof.
US Pat. No. 10,189,885

NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME

The Trustees of the Unive...

1. An immunogenic composition comprising a recombinant protein comprising a listeriolysin O (LLO) protein comprising a mutation of amino acid residues on positions 2, 9 and 10 in the cholesterol-binding domain (CBD) of said LLO protein, said CBD is set forth in SEQ ID NO: 18.
US Pat. No. 10,190,142

HIGH-PURITY GALACTOOLIGOSACCHARIDE COMPOSITIONS, PREPARATIONS, AND APPLICATIONS THEREOF

KING-PREBIOTICS BIOTECHNO...

1. A composition, comprising:a carrier; and
a high-purity galactooligosaccharide composition comprising at least 99% w/w of galactotriose, galactotetraose, and galactooligosaccharide with five or more sugar units;
wherein the high-purity galactooligosaccharide composition consists of 48-57% w/w galactotriose, 25-32% w/w galactotetraose, and 15-22% w/w galactooligosaccharide with five or more sugar units, and lower than 1% w/w of monosaccharides and disaccharides.
US Pat. No. 10,188,605

NANOPARTICLES AND NANOPARTICLE COMPOSITIONS

Iowa State University Res...

1. An organic particle comprising a plurality of non-polymeric crosslinked amphiphiles;wherein the non-polymeric crosslinked amphiphile comprises one or more nonpolar (C6-C60)alkyl or (C6-C50)fluoroalkyl chains and one or more polar head groups;
the nonpolar chains are located on the exterior of the particle and the polar head groups are oriented toward the interior of the particle; and
the amphiphiles are covalently crosslinked to each other near the head groups through thioether groups comprising an ammonium group bonded thereto.
US Pat. No. 10,189,886

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS

Immatics Biotechnologies ...

1. A method of treating a patient who has a cancer overexpressing a SLC7A11 polypeptide comprising the amino acid sequence of SEQ ID NO: 67, comprising administering to said patient a population of activated T cells that kill the cancer cells,wherein the activated T cells are antigen-specific CD8+ cytotoxic T cells produced by contacting CD8+ T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO: 67 in a complex with an MHC molecule class I molecule on the surface of the antigen presenting cell,
wherein said cancer is selected from the group consisting of esophageal cancer and lung cancer, hepatocellular cancer, renal cell cancer, brain cancer, gallbladder cancer, bile duct cancer and head and neck cancer.
US Pat. No. 10,190,143

METHOD FOR SYNTHESIZING SELECTIVELY LABELED RNA

THE BOARD OF REGENTS OF T...

1. A method for synthesizing a RNA, comprising performing an initiation stage, an elongation stage, and a termination stage, wherein:(a) the initiation stage comprises:
(i) providing a solid phase comprising a DNA template, wherein the DNA is attached to a solid substrate;
(ii) providing a first liquid phase comprising a RNA polymerase and ribonucleoside triphosphates (rNTPs);
(iii) mixing the solid phase and first liquid phase;
(iv) incubating the solid phase and first liquid phase at 4-37° C. for 5-30 minutes to initiate synthesis of the RNA;
(v) pausing the RNA synthesis by incubating the solid phase and first liquid phase at 0-5° C., whereupon the solid phase comprises the RNA polymerase and the RNA being synthesized; and
(vi) separating the solid phase from the first liquid phase;
(b) the elongation stage comprises:
(i) providing a second liquid phase comprising rNTPs;
(ii) mixing the solid phase and second liquid phase;
(iii) incubating the solid phase and second liquid phase at 4-37° C. for 5-20 minutes to elongate the RNA;
(iv) pausing the RNA synthesis by incubating the solid phase and second liquid phase at 0-5° C. for 5-30 minutes;
(v) separating the solid phase from the second liquid phase; and
(vi) repeating steps (i)-(v) of part (b) n times, wherein n is equal to 1-100, and wherein the rNTPs in the second liquid phase are the same or different in each repeat;
(c) the termination stage comprises:
(i) providing a third liquid phase comprising rNTPs;
(ii) mixing the solid phase with the third liquid phase;
(iii) incubating the solid phase and third liquid phase at 4-37° C. for 5-30 minutes; and
(iv) pausing the RNA synthesis by incubating the solid phase and third liquid phase at 0° C. for 5-30 minutes; wherein steps (a)-(c) are repeated multiple times, and wherein rNTPs of at least one of the first liquid phase, the second liquid phase, or third liquid phase comprise a label.
US Pat. No. 10,189,119

SOLDER ALLOY FOR DIE BONDING

Nihon Handa Co., Ltd., (...

1. A solder alloy for die bonding consisting of bismuth, 0.05% by mass to 3.0% by mass of antimony, 0.01% by mass to 1.0% by mass of germanium and inevitable impurities.
US Pat. No. 10,189,887

POLYPEPTIDES AND USES THEREOF FOR REDUCING CD95-MEDIATED CELL MOTILITY

INSERM (INSTITUT NATIONAL...

1. A fusion protein, comprising a polypeptide having an amino acid sequence having at least 96, 97, 98, 99 or 100% identity with an amino acid sequence ranging from an amino-acid residue at position 175 to an amino-acid residue at position 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, or 210 as set forth in SEQ ID NO:1,wherein said polypeptide is fused to a heterologous cell-penetrating peptide.
US Pat. No. 10,190,144

PRODUCTION OF DIRHAMNOSE-LIPID IN RECOMBINANT NONPATHOGENIC BACTERIUM PSEUDOMONAS CHLORORAPHIS

The United States of Amer...

1. A recombinant Pseudomonas chlororaphis that is derived from P. chlororaphis NRRL B-30761, said recombinant P. chlororaphis further comprises an expression vector, wherein said expression vector comprises a promoter operably linked to a heterologous polynucleotide encoding a heterologous Pseudomonas rhamnosyltransferase C, wherein rhlA and rhlB genes in said recombinant P. chlororaphis are operably linked to endogenous promoters.
US Pat. No. 10,188,607

PHARMACEUTICAL FORMULATION OF RACECADOTRIL

Rivopharm SA, Manno, Lug...

1. A method of dry granulating racecadotril in the presence of a diluent and a disintegrant, the diluent being lactose monohydrate, said method being carried out by means of a dry granulation technique by operatinga compaction step with a compaction strength of less than 30 kN and equal to or greater than 4 kN, and
a step of grinding and calibration of the slugs and/or ribbon so as to obtain a granulate in which not more than 50% by weight of the product has a particle size of less than 90 microns.
US Pat. No. 10,190,145

EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION

Sutro Biopharma, Inc., S...

1. A bacterial cell free synthesis system for expressing biologically active proteins comprising:i) a cell free S30 extract of E. coli bacteria having an active oxidative phosphorylation system, containing biologically functioning tRNA, amino acids and ribosomes necessary for cell free protein synthesis and where the bacteria were transformed with genes encoding a disulfide isomerase and a prolyl isomerase wherein the two isomerases are expressed in the bacteria at a total concentration of at least 1 g/liter of extract; and
ii) a nucleic acid encoding a protein of interest, wherein the protein of interest comprises a disulfide bond and a proline residue,
and where a concentration of the protein of interest is increased compared to the sum of the concentration expressed by bacteria separately transformed with individual genes encoding the disulfide isomerase and the prolyl isomerase, and the incubation conditions are otherwise the same.
US Pat. No. 10,189,889

VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A

Baxalta Incorporated, Ba...

1. A polynucleotide comprising the nucleotide sequence of SEQ ID NO:1, wherein the polynucleotide encodes a Factor VIII polypeptide.
US Pat. No. 10,190,402

CONTROLLING A BOTTOM-HOLE ASSEMBLY IN A WELLBORE

Halliburton Energy Servic...

1. A computer-implemented method of controlling a bottom hole assembly (BHA), the method comprising:determining, by a wellbore controller, a first candidate BHA control signal;
generating, by the wellbore controller, an input to a BHA control, the input comprising a perturbation signal superimposed on the first candidate BHA control signal;
controlling, by the wellbore controller, the BHA using the input to the BHA control;
determining, by the wellbore controller, a change in an objective value as a function of the perturbation signal, based on a received downhole sensor measurement; and
generating, by the wellbore controller and based on the change in the objective value, a second candidate BHA control signal.
US Pat. No. 10,189,891

AFFINITY CHROMATOGRAPHY MATRIX

1. An immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z,wherein in at least one of the one or more mutated monomers the amino acid sequence of the monomer is defined by SEQ ID NO: 14, 16, 17, or 18.
US Pat. No. 10,190,148

METHOD FOR OBTAINING PEPTIDES

1. Method of obtaining peptides from procaryotic and/or eucaryotic cells, said method comprising the following steps:a) lysis of the procaryotic and/or eucaryotic cells at a low concentration of chaotropic agent(s) and recovery of the proteins thus obtained, wherein the lysis at a low concentration of chaotropic agent(s) comprises lysis by sonication performed by means of an ultrasound probe;
b) denaturation of said proteins using at least one denaturing agent,
wherein the denaturing agent is selected from the group consisting of chaotropic agents, thiol reducing agents, detergents, and combinations thereof, and
wherein the lysis and denaturation steps are performed simultaneously;
c) alkylation of the denatured proteins using at least one alkylating agent;
d) enzymatic proteolysis of the proteins obtained at the end of step c) using at least one proteolytic enzyme;
e) recovery of the peptides obtained at the end of the enzymatic proteolysis step d); and
wherein said method is performed under a pressure below 100 bars.
US Pat. No. 10,188,611

STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA METHYLBUTYRIC ACID

Capsugel Belguim NV, Bor...

1. A liquid filled hard capsule, comprising:a hard capsule shell comprising hydroxypropyl methyl cellulose; and
a liquid fill inside the hard capsule shell comprising an effective amount of beta-hydroxy-beta-methylbutyric acid (HMB free acid) in liquid form and at least one excipient selected from quaternary ammonium salts, amino acids, amino acid derivatives, fructose, and/or any mixture thereof;wherein the excipient is present from about 30% w/w to about 60% w/w of the liquid fill and the liquid filled hard capsule is physically stable.
US Pat. No. 10,189,892

FERMENTATION PROCESS FOR ANTIBODY PRODUCTION

ALDERBIO HOLDINGS LLC, L...

1. A method for producing a recombinant protein in yeast cells, comprising the steps of:a) culturing under fed-batch fermentation conditions a population of yeast cells in a culture medium, wherein each yeast cell comprises a DNA segment encoding a polypeptide, wherein said DNA segment is operably linked to a glyceraldehyde-3-phosphate (GAP) transcription promoter and a transcription terminator, wherein the protein is not glyceraldehyde-3-phosphate, wherein the fermentation comprises a fermentable sugar feed at a first feed rate and wherein the fermentation is agitated at a first oxygen transfer rate;
b) measuring respiratory quotient (RQ) of the population during the batch fermentation and determining if it is within a desired predetermined range, wherein the desired predetermined range of RQ at about 20-40 hours after initiation of the culturing consists of a range between 1.08 and 1.35, which corresponds to a mixed metabolic condition wherein both aerobic and fermentative metabolism are taking place simultaneously;
c) adjusting one or both of the fermentable sugar feed rate to a second feed rate or the oxygen transfer rate to a second oxygen transfer rate, when the RQ is outside of a desired predetermined range;
d) repeating steps (b) and (c) one or more times throughout the step of culturing;
e) harvesting the yeast cells from the culture medium; and
f) recovering the polypeptide from the cells and/or the culture medium.
US Pat. No. 10,188,099

HIGH DENSITY CELL BANKING METHODS

GENZYME CORPORATION, Bos...

1. A non-centrifugal method for producing a high-density frozen mammalian cell bank, the method comprising:a) culturing mammalian cells in a perfusion bioreactor to a first cell density by continuously removing growth medium from a culture and replacing with fresh growth medium, wherein the bioreactor is coupled to a cell retention system comprising an alternating tangential flow filtration system including a filter;
b) non-centrifugally concentrating the cells cultured in the perfusion bioreactor coupled to the cell retention system, wherein the cells are concentrated to a second cell density greater than the first cell density by removing the growth medium from the culture using the filter and, thereby reducing the volume of the growth medium to produce a concentrated cell population of about 1×108 cells/mL; and
c) cryopreserving the concentrated cell population to produce a high-density frozen mammalian cell bank,
wherein the high-density frozen mammalian cell bank has a post-thaw viability of at least 90%.
US Pat. No. 10,188,612

PHARMACEUTICAL COMPOSITIONS FOR INHALATION

Vectura Limited, Wiltshi...

1. Microparticles for use in a pharmaceutical composition for pulmonary administration, comprising particles of an active substance having on their surfaces particles of a hydrophobic material comprising magnesium stearate to promote the dispersal of the active particles on actuation of an inhaler or to delay the dissolution of the active substance in an aqueous medium, wherein the particles of hydrophobic material are applied to the particles of active substance experiencing a high shear force, wherein the microparticles comprise an effective amount of one or more of the substances selected from the group consisting of antimuscarinic, a ?2-agonist, a steroid, a peptide and a polypeptide, and wherein, upon inhalation of the microparticles, the active substance exerts its pharmacological effect over a period significantly greater than the period over which the active substance exerts its pharmacological effect when inhaled alone.
US Pat. No. 10,188,613

EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT

UNIVERSITY OF SOUTH FLORI...

1. A method of treating a medical condition selected from the group consisting of substance addiction, Tourette's Syndrome, a neuropsychiatric disorder, depression, and anxiety, in a human in need thereof, comprising orally administering a therapeutically effective amount of a pharmaceutical composition to the human, wherein the pharmaceutical composition comprises:exo-S-mecamylamine or pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof,
one or more pharmaceutically acceptable carriers; and
a pharmaceutical adjuvant, wherein the pharmaceutical composition has a higher overall therapeutic index than the same amount of exo-R-mecamylamine substantially free of exo-S-mecamylamine.
US Pat. No. 10,189,895

ANTI-CGRP COMPOSITIONS AND USE THEREOF

ALDERBIO HOLDINGS LLC, L...

1. A pharmaceutical composition comprising a humanized anti-calcitonin gene related peptide (CGRP) antibody comprising a variable light (VL) chain polypeptide comprising the complementarity-determining region (CDR) polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 57, and a variable heavy (VH) chain polypeptide comprising the CDR polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, and a pharmaceutically acceptable excipient.
US Pat. No. 10,190,151

HIGH-THROUGHPUT AND HIGHLY MULTIPLEXED IMAGING WITH PROGRAMMABLE NUCLEIC ACID PROBES

President and Fellows of ...

1. A method comprising(1) contacting a sample being tested for the presence of one or more targets with one or more target-specific binding partners, wherein each target-specific binding partner is linked to a docking strand, and wherein target-specific binding partners of different specificity are linked to different docking strands to produce one or more targets bound to one or more target-specific binding partners,
(2) optionally removing unbound target-specific binding partners,
(3) contacting the sample with labeled imager strands that bind to docking strands,
(4) optionally removing unbound labeled imager strands,
(5) imaging the sample to detect bound labeled imager strands,
(6) inactivating the bound labeled imager strands, by removing or modifying their signal-emitting moieties without removing the imager strand in its entirety, and
(7) repeating at least some of steps (3)-(6) at least once with a labeled imager strand having a unique composition relative to at least one other labeled imager strand of step (3).
US Pat. No. 10,188,101

METHOD FOR PRODUCING AN AGRICULTURAL PRODUCT

KAO CORPORATION, Tokyo (...

1. A method for producing an agricultural product, comprising a step of applying an agricultural chemical composition comprising (A) at least one compound selected from the group consisting of the following (A1) to (A5); (B) at least one compound selected from the group consisting of the following (B1) and (B2); and an agricultural chemical ingredient selected from the group consisting of active ingredients in bactericides, pesticides, miticides, herbicides and plant growth regulators to a subject sensitive to the agricultural chemical ingredient:(A1): a polyoxyethylene alkyl ether represented by the formula (A1):
R1aO-(EO)l—R2a  (A1)
wherein, R1a represents a linear or branched, alkyl or alkenyl group having 10 to 16 carbon atoms; EO represents an ethyleneoxy group; 1 represents an average mole number of ethyleneoxy groups added, ranging from 3 to 40; and R2a represents a hydrogen atom or a methyl group,
(A2): a polyoxyethylene fatty acid ester,
wherein a fatty acid group has 8 to 16 carbon atoms; and an average number of moles of ethylene oxide added per mole of fatty acid is 5 to 40,
(A3): a polyoxyethylene sorbitan fatty acid ester,
wherein a fatty acid group has 8 to 16 carbon atoms; and an average number of moles of ethylene oxide added per mole of fatty acid is 5 to 40,
(A4): a (poly)glycerol fatty acid ester,
wherein a fatty acid group has 8 to 16 carbon atoms; and an average condensation degree of glycerol is 1 to 3, and
(A5): an alkyl saccharide represented by the formula (A5):
R3a—O-(G)p  (A5)
wherein R3a represents an alkyl group having 8 to 16 carbon atoms; G represents a reducing sugar group having 5 to 6 carbon atoms; and p represents a number of 1 to 10;
(B1): a polyoxyalkylene alkyl ether represented by the formula (B1):
R1bO—[(PO)m/(EO)n]—R2b  (B1)
wherein, R1b represents a linear or branched, alkyl or alkenyl group having 6 to 12 carbon atoms; PO represents a propyleneoxy group; EO represents an ethyleneoxy group; m represents an average mole number of propyleneoxy groups added, ranging from 2 to 20; n represents an average mole number of ethyleneoxy groups added, which is 0; and R2b represents a hydrogen atom or a methyl group; wherein “/” means that PO and EO groups may be arranged at random or in blocks, and
(B2): an aliphatic alcohol represented by the formula (B2):
R3b—OH  (B2)
wherein R3b represents a linear or branched, alkyl group having 8 to 10 carbon atoms, and wherein a weight ratio of compounds (A) to (B), (A)/(B), is 0.5 to 8.
US Pat. No. 10,188,614

PARTICULATE MATERIALS

Nektar Therapeutics, San...

1. An active substance in particulate form suitable for administration via a dry powder inhaler, said particulates comprising:a) a volume mean aerodynamic diameter of less than 7 microns;
b) a density less than 0.5 g/ml; and
c) a surface-to-volume ratio of at least twice that of spherical particles of the same volume diameter.
US Pat. No. 10,190,152

METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS

Becton, Dickinson and Com...

1. A composition consisting of a direct chemical lysis composition in combination with a liquid-based cytology sample or a formalin-fixed, paraffin embedded sample, the direct chemical lysis composition consisting of:a) a buffer composition comprising a buffer component and a metal salt component, wherein the metal salt component is selected from the group consisting of sodium chloride (NaCl), potassium chloride (KCl), sodium acetate (C2H3NaO2) and ammonium sulfate ((NH4)2SO4), wherein a concentration of the buffer component is in a range of 0.2 M to 2 M and a concentration of the metal salt component is in a range of 0.01 M to 1 M; and
b) a non-ionic surfactant wherein a concentration of the non-ionic surfactant is in a range of 0.01 to 2 percent (v/v).
US Pat. No. 10,188,102

LOW FOAM SURFACTANT COMPOSITION AND METHODS OF MAKING THE SAME

Momentive Performance Mat...

1. A low foam surfactant composition comprisinga) di-trisiloxane alkoxylate component of formula (I):
(R1R2R3SiO)2(R4)Si—R5—Si(R6)(OSiR7R8R9)2  (1)
where R1, R2, R3, R4, R6, R7, R8 and R9 each independently is methyl, ethyl or linear or branched monovalent hydrocarbon radical of 3 or 4 carbon atoms,
R5 is a divalent polyalkyleneoxide group of the structure:
—(R10)aO(C2H4O)b(C3H6O)c(C4H8O)d—(R11)e—
where R10 and R11 each independently is a linear or branched divalent hydrocarbon radical of from 2 to 6 carbon atoms, a and e each independently is 0 or 1, b is 0 or greater, c is 1 or greater, and d is 0 or greater, provided that 1?b+c+d?20; and,
b) mono-trisiloxane alkoxylate component of formula (II):
(R12R13R14SiO)2Si(R15)R16  (11)
where R12, R13, R14 and R15 each independently is a linear or branched monovalent hydrocarbon radical of from 1 to 4 carbon atoms, and
R16 is a monovalent polyalkyleneoxide group of the structure:
—R17O(C2H4O)g(C3H6O)h(C4H8O)i—R18
where —R17 is a linear or branched divalent hydrocarbon radical of from 2 to 6 carbon atoms,
R18 is hydrogen, monovalent hydrocarbon radical of from 1 to 4 carbon atoms or acetyl, and g, h and i each independently is 0 or greater, provided that 1?g+h+i?15;
and, wherein di-trisiloxane alkoxylate (I) is soluble in mono-trisiloxane alkoxylate (II).
US Pat. No. 10,188,615

ALKOXY COMPOUNDS FOR DISEASE TREATMENT

ACUCELA INC., Seattle, W...

1. A method of modulating chromophore flux in a retinoid cycle comprising introducing into a subject a non-retinoid aromatic compound that inhibits 11-cis-retinol production with an IC50 of about 0.1 micromolar or less when assayed in vitro, the assay consisting of a homogenate of HEK293 cell clone expressing recombinant human RPE65 and LRAT as the source of visual enzyme, exogenous all-trans-retinol in the amount of about 20 ?M, recombinant human CRALBP in the amount of about 80 ?g/mL, about 10 mM pH 7.2 phosphate buffer, about 0.5% BSA and about 1 mM NaPPi, and wherein the amount of assay reaction product 11-cis-retinol being determined by HPLC analysis following heptane extraction of the assay reaction mixture and wherein the non-retinoid aromatic compound consists of a benzene core that is substituted with a first substituent, a second substituent, and an optional third substituent, wherein the first and second substituents are attached to the benzene core in a meta-substitution configuration, wherein the first substituent is a group selected from —CH(OH)CH(R)CH2NH2 wherein R is H, CH3, or —OH and the second substituent is an optionally substituted alkoxy group, and wherein the optional third substituent is a halogen or —OH.
US Pat. No. 10,189,897

PROTEIN PURIFICATION

UCB PHARMA, S.A., Brusse...

1. A process for the purification of an antibody fragment comprising:a) a first chromatography step to capture the antibody fragment wherein a periplasmic cell extract containing bacterial host cell protein in an amount of about 200 ?g/ml to 10,000 ?g/ml and an antibody fragment at a concentration of at least 1.5 g/L is subjected to cation exchange chromatography and subsequently eluted to produce a first eluate containing the antibody fragment; and
b) a second chromatography step wherein the first eluate is subjected to anion exchange chromatography to capture impurities and produce a flow through containing the antibody fragment.